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Zusammenfassung der Habilitationsschrift 
 
For at least two decades, the health care expenditures of virtually all industrialised countries 
have been increasing faster than gross domestic products. In this situation, health care 
sectors are rarely perceived as contributors to the creation of societal value but are rather 
associated with a - much debated - cost problem. At the health system level, most countries 
have experimented with interventions in the fields of health care financing, health insurance, 
and reimbursement of health care providers. Managed care and patient co-payments were 
introduced or extended. The successes of these measures were highly variable and 
sometimes, dysfunctional effects (e.g. unintended rationing) were triggered. The field of 
macro-level health economics strives to address these issues. 
 
In parallel, but more at the meso- and micro-levels, health economic evaluation aims at 
contributing to a more rational use of health care resources by analysing the costs and 
benefits of individual medical interventions, or groups of interventions, as a basis for decision 
making. According to the underlying paradigm, the final goal is to achieve an optimal use of 
limited resources, and thus maximise population health. Therefore, full-scale health 
economic evaluation studies (cost-effectiveness and cost-utility analyses) always imply two 
sides of a coin: an integration of clinical and economic evidence. Other health economic 
studies, such as budget impact analyses, cost-of-illness studies and studies of the medical 
resource use associated with disease entities or medical interventions, are more limited in 
scope but provide important auxiliary information. Epidemiological studies contribute 
background data on patterns of disease occurrence (incidence, prevalence, and 
geographical distribution). Moreover, studies with a clinical epidemiology or primarily clinical 
focus can at times yield important direct hints on how health care resources can be used 
more efficiently. This is for example the case where genetic or biological markers are 
identified that allow predict if an expensive treatment will be effective in a given patient, or 
where risk factors for diseases, clinical events or treatment side effects can be identified and 
used to efficiently target screening and preventive measures. 
 
The following six publications selected for habilitation span most of the above-described 
range of possibilities. They all have, in a less or more direct manner, implications for the 
efficient use of medical resources. The first publication introduces and discusses risk models 
for the occurrence of febrile neutropenia in patients with non-Hodgkin lymphoma undergoing 
chemotherapy [1]. The second publication, a research letter, establishes a link between 
reduced chemotherapy delivery, a frequent consequence of myelosuppression, and long-
term survival, in patients with the same disease [2]. In the third publication, the clinical and 
medical resource use implications of severe oral mucositis, another major side effect of anti-
malignant chemotherapy, are assessed [3]. The forth publication reports a population-
representative cross-sectional study of gastroesophageal reflux disease and its cost-of-
illness implications [4]. The last two papers describe modelling studies of postmenopausal 
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osteoporosis. The first predicts future osteoporotic fracture occurrence in Switzerland and its 
economic consequences for the health system [5]. The second reports a full-scale health 
economic evaluation of the implications of adopting a population-based screening strategy 
for osteoporosis, with subsequent treatment where applicable, in Switzerland [6]. 
 
The febrile neutropenia risk model publication is based on a prospective observational study 
of patients from five European countries. The multivariate risk models proposed require 
further validation but appear to have the potential to predict febrile neutropenia with good 
precision. In particular, low risk patients are successfully identified. This may allow to better 
target, and hence improve the cost-effectiveness of, expensive prophylactic measures. A 
randomised clinical trial with an accompanying health economic sub-study should ideally be 
conducted to confirm this potential, if initial external validation of the risk models is 
successful. 
 
As a side-finding, the analysis of febrile neutropenia occurrence demonstrates that patient 
risk is influenced by patient and treatment characteristics but also by clinical practice 
patterns, e.g. the tendency to delay chemotherapy cycles or reduce doses. In consequence, 
the administered chemotherapy dose intensity (a composite measure of dose and timeliness 
of delivery) can be substantially compromised. The second publication shows a negative 
impact of compromised chemotherapy delivery on long-term survival, based on data from 
two independent retrospective studies conducted in Belgium and Great Britain. Apparently, 
administering full chemotherapy dose intensity is important enough to justify expenditures on 
prophylactic measures. Again, further study is required and could be accompanied by a 
formal health economic assessment. 
 
The oral mucositis publication is based on a pan-European prospective observational study 
of patients with non-Hodgkin lymphoma and multiple myeloma. By linking the clinical 
correlates of oral mucositis with medical resource use implications, it is shown that better 
management of this adverse condition would not only improve patient well-being but might 
also lead to savings. This notion is supported by a Poisson regression analysis of influences 
on duration of hospitalisation which includes severe oral mucositis occurrence as a highly 
significant predictor variable. 
 
Telephone surveys are a valid and efficient alternative approach to gain information on the 
occurrence (prevalence, in the present case) of frequent medical conditions and the structure 
of associated medical resource use and costs, as is exemplified by the study on 
gastroesophageal reflux disease. The contributions of different cost components are shown 
and patient characteristics associated with increased total costs (e.g. urban versus rural 
dwelling) are identified. Such information supports the planning and development of health 
services and provides input data for subsequent health economic modelling. 
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The publications on osteoporosis are literature-based and make use of decision-analytic 
modelling techniques. A Markov model of osteoporotic fracture occurrence was developed 
and populated with demographic scenarios provided by the Swiss Federal Statistical Office, 
published epidemiological data, and publicly available Swiss data on duration of 
hospitalisation, nursing home residency and cost per day of stay. Fracture numbers and the 
burden to the Swiss health care budgets are projected until 2020. 
 
The original Markov model was adapted to perform a cost-utility analysis of a population-
based screen-and-treat strategy for osteoporosis (dual X-ray absorptiometry followed by 
bisphosphonate (alendronate) treatment if osteoporosis, or osteopenia and a fracture, were 
found to be present) from the perspective of the Swiss health care system. Population-based 
screening was found to be cost-effective in women aged 75 or older but not in men. 
Internationally, several other studies assessed the cost-effectiveness of alendronate but 
most of them used unrealistic compliance assumptions, disregarded the process of 
screening and diagnosis, or ignored disease-related events that occurred before a defined 
screening age. It is shown in the publication that the latter has led to too optimistic 
judgements on the benefits of screening later in life. The main limitation of the present 
analysis is that, due to a lack of data, it could not be assessed to what extent cost-
effectiveness could be improved by targeting the screening to persons with known risk 
factors for osteoporosis or falls. Further work is currently being planned to address this issue. 
 
In conclusion, independent of macro-level interventions, improving the efficiency of health 
care on the basis of emerging scientific evidence and rational decision making can contribute 
to patient well-being and cost-containment. In some cases, clinical epidemiology or primarily 
clinically oriented studies make direct contributions to this goal, by providing information that 
helps to better target screening, prevention, or treatment. In these situations, it is 
fundamental to achieve a thorough understanding of the underlying disease process and to 
ensure that any identified associations between predictors and risk factors on the one hand, 
and patient outcomes on the other hand, are valid. This typically implies the use of 
appropriate techniques of multivariate statistical analysis and independent validation. In other 
cases, explicitly health economic studies are needed to generate a sufficient knowledge base 
for improving the efficiency of health care delivery. Such studies often make use of decision-
analytic modelling techniques, in order to integrate data from different sources and to 
extrapolate beyond the limited observation times of most randomised clinical trials. In these 
cases, careful selection of model input parameters, transparency, appropriate sensitivity 
analyses, and adherence to good modelling practice guidelines are of paramount 
importance. At the same time, oversimplification must be avoided. As is shown in the last of 
the publications selected for habilitation, health economic models must not ignore important 
elements of the disease and medical management process, such as disease occurrence 
before a given screening age. Otherwise, biased results may occur that cannot be detected 
by standard sensitivity analyses, and the goal of improving the efficiency of health care 
delivery may not be achieved. 
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Multivariate analysis of febrile neutropenia occurrence in
patients with non-Hodgkin lymphoma: data from the INC-EU
Prospective Observational European Neutropenia Study
Chemotherapy-induced neutropenia (CIN) is a frequent and
potentially serious adverse effect of cancer treatment (Dale
et al, 2003). Lymphoma patients with CIN who develop febrile
neutropenia (FN) are typically hospitalised and treated with
intravenous antibiotics (Dale et al, 2003; Crawford et al, 2004;
Nijhuis et al, 2005; Aapro et al, 2006; Klastersky & Paesmans,
2007). A common response to CIN is to reduce or delay
delivery of chemotherapy treatment (Dale et al, 2003;
Schwenkglenks et al, 2006); however, decreased dose intensity
has been associated with increased morbidity and mortality in
patients treated with curative intent (Kwak et al, 1990; Lepage
et al, 1993; Bonadonna et al, 1995; Budman et al, 1998; Bosly
et al, 2008; Pettengell et al, 2008a); indicating that patient
outcome is improved when the intensity of chemotherapy
treatment is optimal (Bosly et al, 2008).
Colony-stimulating factors (CSFs) are used to reduce the risk
of developing neutropenic complications and to facilitate
delivery of planned chemotherapy dose (Komrokji & Lyman,
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Summary
Myelosuppression, particularly febrile neutropenia (FN), are serious dose-
limiting toxicities that occur frequently during the first cycle of
chemotherapy. Identifying patients most at risk of developing FN might
help physicians to target prophylactic treatment with colony-stimulating
factor (CSF), in order to decrease the incidence, or duration, of
myelosuppression and facilitate delivery of chemotherapy as planned. We
present a risk model for FN occurrence in the first cycle of chemotherapy,
based on a subgroup of 240 patients with non-Hodgkin lymphoma (NHL)
enroled in our European prospective observational study. Eligible patients
had an International Prognostic Index of 0–3, and were scheduled to receive a
new myelosuppressive chemotherapy regimen with at least four cycles.
Clinically relevant factors significantly associated with cycle 1 FN were older
age, increasing planned cyclophosphamide dose, a history of previous
chemotherapy, a history of recent infection, and low baseline albumin
(<35 g/l). Prophylactic CSF use and higher weight were associated with a
significant protective effect. The model had high sensitivity (81%) and
specificity (80%). Our model, together with treatment guidelines, may
rationalise the clinical decision of whether to support patients with CSF
primary prophylaxis based on their risk factor profile. Further validation is
required.
Keywords: Non-Hodgkin lymphoma, neutropenia, chemotherapy, risk fac-
tors.
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2004; Aapro et al, 2006; Smith et al, 2006). Physicians wishing
to identify those patients that should be supported with
prophylactic CSF are faced with an array of patient-related and
treatment-related factors to consider. Current guidelines
recommend CSF support for chemotherapy treatment regi-
mens associated with a high risk of FN (>20%) (Aapro et al,
2006; Smith et al, 2006). One such regimen is combination
chemotherapy with cyclophosphamide, doxorubicin, vincris-
tine and prednisone (CHOP), which has long been the standard
treatment for patients with aggressive non-Hodgkin lymphoma
(NHL) (Fisher et al, 1993). The addition of rituximab to the
CHOP regimen (R-CHOP) has further improved patient
outcomes (Coiffier et al, 2002; Pfreundschuh et al, 2006;
National Comprehensive Cancer Network Inc, 2008a), making
R-CHOP the current standard of care (National Comprehen-
sive Cancer Network Inc, 2008a). CHOP-like chemotherapy
carries a significant risk of FN (17–50%) (Morrison et al, 2001;
Lyman et al, 2003; Osby et al, 2003; Aapro et al, 2006; Bosly
et al, 2008; Pettengell et al, 2008b). In addition to the risk
associated with the chemotherapy regimen, other risk factors
should be considered in order to determine the patient’s overall
FN risk (Aapro et al, 2006; Smith et al, 2006; National
Comprehensive Cancer Network Inc, 2008b).
Several retrospective studies have identified potential risk
factors for FN in lymphoma patients, including older age, low
baseline blood cell counts, low serum albumin, anaemia,
abnormal bone marrow, increased lactate dehydrogenase
(LDH), co-morbid renal, cardiovascular or hepatic disease,
full or high-risk planned chemotherapy regimen, and lack of
CSF prophylaxis (Lyman & Delgado, 2003; Lyman et al, 2005;
Rabinowitz et al, 2006; Teegala et al, 2007). However, it is not
possible to give a weighting to these risk factors and accurately
determine their individual importance. The potential for risk
factors identified in retrospective studies to guide targeted CSF
use needs to be validated in prospective investigations.
Early, prospective clinical models in lymphoma patients not
receiving CSF prophylaxis identified high levels of serum LDH
and tumour necrosis factor (TNF) and bone marrow involve-
ment as risk factors for FN (Intragumtornchai et al, 2000; Voog
et al, 2000). Data from several large prospective registries have
led to the development of risk models for chemotherapy-
induced FN, and the risk factors they have identified are broadly
consistent with those highlighted by retrospective studies (Casas
et al, 2006; Lyman et al, 2006; Shayne et al, 2007a). However,
these studies were in patients with solid tumours (Casas et al,
2006) or in patients with solid tumours or lymphoma (Lyman
et al, 2006; Shayne et al, 2007a), and therefore did not specif-
ically examine the risk of FN in lymphoma patients.
Several studies have demonstrated that the risk of FN is
greatest in the first cycle of chemotherapy, with >50% of
patients who develop FN experiencing an episode during cycle
one (Lyman & Delgado, 2003; Lyman et al, 2003). The Impact
of Neutropenia in Chemotherapy – European Study Group
(INC-EU) Prospective Observational European Neutropenia
Study was conducted to assess the incidence and predictors of
neutropenia, FN and reduced chemotherapy administration
for breast cancer and lymphoma patients in European
practices. Multivariate regression models for lymphoma
patients indicated that first cycle FN, age ‡65 years, disease
status, and type of chemotherapy regimen predicted low
relative dose intensity (RDI), while primary prophylaxis with
CSF was protective (Pettengell et al, 2008b).
Here we present a subgroup analysis of NHL patients from
the INC-EU prospective study with the aim of establishing a
multivariate risk model of FN occurrence in the first cycle of
chemotherapy. Such models may help to target high-risk
patients for prophylactic treatment in order to decrease the
incidence of myelosuppression and enable full-dose chemo-
therapy to be delivered on schedule.
Methods
Study design and patient selection
Data were obtained for 749 patients with histologically
confirmed breast cancer, NHL and Hodgkin lymphoma (HL)
who were enrolled in the INC-EU Prospective Observational
European Neutropenia Study between January 2004 and May
2005. A subset of 240 patients with NHL were included in this
sub-analysis. The study was conducted in 66 centres in
Belgium, France, Germany, Spain and the UK. Of these, 39
centres contributed NHL patients for this subanalysis. Ethical
approval was obtained from the institutional review boards of
all centres. Patients with NHL and an International Prognostic
Index (IPI) of 0–3, and who were scheduled to receive a new
myelosuppressive chemotherapy regimen with at least four
cycles, were eligible for inclusion. All participants provided
their informed consent. Further details of the overall study
design and patient selection have been described previously
(Pettengell et al, 2008b).
Statistical methods
Multivariate logistic regression models of FN occurrence in
cycle 1 were developed. In line with established definitions (e.g.
National Comprehensive Cancer Network Inc, 2008b), FN was
defined as Grade 4 CIN [absolute neutrophil count (ANC)
<0Æ5 · 109/l] and a body temperature ‡38°C. General esti-
mating equations (GEE)-based robust standard error (SE)
estimates were used to allow for clustering by study centre. The
impact of this choice was assessed by comparison with results
based on conventional SE estimates.
Candidate predictors were selected based on clinical and
statistical grounds (P £ 0Æ25 in univariate analysis). To rule
out circularity effects, potential direct correlates of the
dependent variables of interest were not used. In the model-
building process, main effects were identified by manually
exploring all plausible combinations of covariates. A model for
the occurrence of FN in any cycle of chemotherapy was also
developed using similar techniques.
R. Pettengell et al
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In an effort to make full use of the available information,
missing categories were introduced for candidate predictors
with more than 5% missing values. Concerns have been raised
that this approach can lead to biased estimation results,
particularly where covariates have a high proportion of missing
values and are strong confounders (Vach & Blettner, 1991;
Greenland & Finkle, 1995). Therefore, as an additional
sensitivity analysis, alternative models omitting all covariates
with more than 5% missing values were estimated and the
parameter estimates and standard errors for the remaining
covariates were assessed for deviations; these sensitivity
analyses did not reveal any relevant distortions.
The Hosmer–Lemeshow goodness of fit test and plots of
mean observed versus mean predicted event probabilities, by
deciles of the linear predictor, were used to assess model fit.
The risk of cycle 1 FN is presented as an odds ratio (OR) with
95% confidence interval (CI). Predictive ability of the models
was characterised by sensitivity (percentage of the FN occur-
rences that were correctly predicted) and specificity (percent-
age of the FN non-occurrences that were correctly predicted),
positive predictive value (percentage of patients predicted to
have an FN who had FN), negative predictive value (percent-
age of patients predicted not to have an FN who did not have
FN), the area under the receiver operating characteristic
(ROC) curve, and the total proportion of correct predictions.
Additionally, in the absence of an independent validation
dataset, 10-fold cross-validation was performed. In a final step,
the model was applied to hypothetical scenarios.
Variables considered for multivariate models
The following variables were considered for logistic regression
model building for both cycle 1 FN and any cycle FN: previous
chemotherapy (vs. chemotherapy-naı¨ve); planned doses (for
sequential regimens, of first part of chemotherapy); chemo-
therapy treatment within a clinical trial protocol; CSF
prophylaxis (for the purpose of statistical modelling, defined
as any CSF use before a FN occurred); antibiotic prophylaxis
(for the purpose of statistical modelling, defined as any
cotrimoxazole or quinoline use before a FN occurred) cancer
stage (Ann Arbor); number of haematology laboratory tests
before a grade IV CIN occurred; recent infection (<60 d prior
to start to chemotherapy); baseline ANC <3Æ0 · 109/l; baseline
white blood cell count (WBC) <5Æ0 · 109/l; baseline haemo-
globin <100 g/l; baseline glucose >8Æ8 mmol/l; baseline albu-
min <35 g/l; baseline total bilirubin >17Æ1 lmol/l; baseline
alkaline phosphatase >250 IU/l; number of comorbidities at
baseline; cardiac comorbidity at baseline; vascular comorbidity
at baseline; cardiovascular comorbidity at baseline; liver
disease at baseline; renal comorbidity at baseline; age; glomer-
ular filtration rate (GFR; estimated using the Cockcroft-Gault
formula); height; weight; body surface area (BSA); and body
mass index (BMI). Assessment of comorbidities at baseline
used Medical Dictionary for Regulatory Activities (Med-
DRAÒ)-coded medical history entries with the following
system organ class and preferred term names: cardiac dis-
orders; vascular disorders; renal and urinary disorders; hepa-
tobiliary disorders; infections and infestation; diabetes
mellitus. For the any cycle model, the following covariates
were also considered: planned dose intensities (for sequential
regimens, of first part of chemotherapy); use of a dose dense
regimen (cycle length 2 weeks instead of 3 weeks); planned
cycle length; planned cycle number; dose reduction (‡10% of
planned dose of at least one drug in at least one cycle) before
FN occurred; and dose delay (a delay ‡4 d in at least one cycle)
before FN occurred.
Results
Patient and baseline disease characteristics are shown in
Table I. The majority of patients (75%) received a CHOP-21-
like treatment regimen and a high percentage (82%) of
patients received rituximab (Table II). An average of six
chemotherapy cycles were planned (mean 6Æ2, SD 1Æ5). Overall,
28% of patients received primary CSF prophylaxis and 29%
had other CSF use. CSFs used were: filgrastim, 40%; pegfil-
grastim, 34%; lenograstim, 10%. The remaining 16% of
patients with any CSF use received two or three of these
substances. Primary antibiotic prophylaxis with cotrimoxazole
was seen in 8% of patients and prophylaxis with quinolones in
14%. During cycle 1, FN occurred in 9% of patients and the
incidence of FN across all cycles of chemotherapy was 22%
(Fig 1). Grade IV CIN occurred in 35% of patients in cycle 1
and in 54% of patients across all cycles.
The results of the multivariate logistic regression analysis
used to model risk factors for cycle 1 FN are shown in
Table III. Clinically relevant factors that were significantly
associated with cycle 1 FN were older age, increasing planned
cyclophosphamide dose, increasing planned etoposide dose, a
history of previous chemotherapy, a history of recent infection,
and low baseline albumin <35 g/l. Prophylactic CSF use and
higher weight were associated with a significant protective
effect. The effect of antibiotic prophylaxis with cotrimoxazole
or quinolones remained non-significant [OR (95% CI): 0Æ36
(0Æ08–1Æ62), P = 0Æ181] when added to the final model.
Replacing age with GFR (to which it is inversely related) and
replacing weight with height yielded similar models.
The model correctly classified 192 of the 240 patients (80%).
The area under the ROC curve, which describes the ability of
the model to discriminate between those at risk from cycle 1
FN and those not at risk, was 0Æ86 (95% CI 0Æ79–0Æ94) (Fig 2).
(An area under the ROC curve of 0Æ5 implies an ability to
discriminate that is no better than chance, while a value of 1
represents perfect ability to discriminate). When the optimal
probability cut-off was used to predict cycle 1 FN, test
characteristics were: sensitivity 81%; specificity 80%; positive
predictive value 28% (proportion of patients classified as high
risk who suffered cycle 1 FN); negative predictive value 98%
(the proportion of patients classified as low FN risk who did
not suffer cycle 1 FN). Predictive ability was only slightly lower
INC-EU Prospective Febrile Neutropenia Risk Model
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under 10-fold cross-validation conditions (area under the
ROC curve 0Æ78).
A similar model was developed to predict the risk of FN in
any cycle. In agreement with the first cycle FN model, the
following factors were also significantly associated with FN
occurrence in any cycle: age [OR (95% CI): 1Æ79 (1Æ16–2Æ78)
per additional 10 years, P = 0Æ009]; increasing planned cyclo-
phosphamide dose [OR (95% CI): 1Æ33 (1Æ16–1Æ52) per
additional 50 mg/m2, P < 0Æ001]; increasing planned etopo-
side dose [OR (95% CI): 1Æ88 (1Æ10–3Æ20) per additional
50 mg/m2, P = 0Æ021]; and recent infection [OR (95% CI):
3Æ32 (1Æ03–10Æ71), P = 0Æ044]. Likewise, prophylactic CSF use
[OR (95% CI): 0Æ21 (0Æ10–0Æ44), P < 0Æ001] and higher weight
[OR (95% CI): 0Æ62 (0Æ44–0Æ88) per additional 10 kg,
P = 0Æ007] were associated with a significant protective effect.
In addition, the following clinically relevant factors were
associated with a significantly increased risk of any cycle FN:
low baseline ANC or WBC [ANC <3Æ0 · 109/l or WBC
<5 · 09/l; OR (95% CI): 4Æ18 (1Æ82–9Æ60), P = 0Æ001], high
baseline alkaline phosphatase [>250 IU/ml; OR (95% CI): 9Æ07
(1Æ41–58Æ50), P = 0Æ020], cardiovascular comorbidity [OR
(95% CI): 2Æ56 (1Æ04–6Æ29), P = 0Æ041], and increasing planned
cytarabine dose [OR (95% CI): 1Æ09 (1Æ05–1Æ13) per additional
50 mg/m2, P < 0Æ001]. Use of a dose dense regimen (cycle
length 2 weeks instead of 3 weeks) may influence FN but did
not attain statistical significance in our model [OR (95% CI):
1Æ84 (0Æ71–78), P = 0Æ208; see Discussion]. In the any cycle
model, dose reductions before an FN event occurred [OR
(95% CI): 0Æ24 (0Æ09–0Æ63), P = 0Æ004] and dose delays before
an FN event occurred [OR (95% CI): 0Æ17 (0Æ07–0Æ40),
P < 0Æ001] had a significant protective effect against FN. In
contrast to the cycle 1 model, a history of chemotherapy [OR
(95% CI): 1Æ76 (0Æ49–6Æ36), P = 0Æ390] and low baseline
albumin [OR (95% CI): 1Æ62 (0Æ54–4Æ85) P = 0Æ391 when
added to the final model] were non-significant in the any cycle
model. Antibiotic prophylaxis showed no effect.
The any cycle model correctly classified 180 of 237 patients
(76%). The area under the ROC curve was 0Æ83 (95% CI 0Æ76–
0Æ90). When the optimal probability cut-off was used to
predict any cycle FN, test characteristics were: sensitivity 76%;
specificity 76%; positive predictive value 48%; negative
predictive value 92%. Predictive ability was slightly lower
under 10-fold cross-validation conditions (area under the
ROC curve 0Æ72).
Based on our models, the estimated risk of FN in cycle 1 or
any cycle during R-CHOP therapy for lymphoma (without
CSF prophylaxis) in a hypothetical 80 kg subject (average
weight of our male subsample) is shown in Table IV. The risk
of FN increased as the number of risk factors and age increased
in both models. Assigning a lower weight (e.g. 55 kg) to the
subject increased the risk for all possible scenarios shown in
Table IV.
Discussion
This study identified several clinically relevant factors that were
predictive or protective for cycle 1 FN. Patient and baseline
characteristics of older age and low baseline albumin were
predictive of cycle 1 FN, as were a clinical history of previous
chemotherapy or recent infection. Treatment characteristics,
specifically increasing planned chemotherapy dose, also sig-
nificantly increased risk of cycle 1 FN. In contrast, higher
weight and prophylactic CSF use were associated with
significant protective effects.
Older age (>65 years) is recognised as a risk factor for FN by
current European guidelines (Aapro et al, 2006). Indeed,
Table I. Patient and baseline disease characteristics (n = 240).
Characteristic
Age (years), mean ± SD (range) 63Æ2 ± 12Æ9 (17–90)
Female gender, n (%) 105 (43Æ8)
Height (cm), mean ± SD (range) 169Æ9 ± 9 (145–194)
Weight (kg), mean ± SD (range) 75 ± 16 (41–176)
BSA (m2), mean ± SD (range) 1Æ8 ± 0Æ2 (1Æ3–2Æ4)
GFR (ml/min), mean ± SD (range)* 82Æ9 ± 30Æ7; (21Æ6–264Æ0)
REAL classification, n (%)
Diffuse large cell 154 (64Æ2)
Follicular 35 (14Æ6)
Mantle cell 12 (5Æ0)
Other 36 (15Æ0)
Unknown 3 (1Æ3)
Ann Arbor staging, n (%) 
I 42 (17Æ7)
II 62 (26Æ2)
III 39 (16Æ5)
IV 94 (39Æ7)
B symptoms, n (%)  113 (47Æ7)
IPI score, n (%) 
Low (0–1) 75 (31Æ7)
Intermediate (2–3) 132 (55Æ7)
High (‡4) 30 (12Æ7)
No. of comorbidities,
mean ± SD (range)
2Æ1 ± 2Æ1 (0–11)
Cardiovascular comorbidity, n (%) 65 (27Æ1)
Cardiac comorbidity n (%) 32 (13Æ3)
Liver comorbidity n (%) 5 (2Æ1)
Renal comorbidity n (%) 16 (6Æ7)
Recent infection, n (%)à 11 (4Æ6)
Previous chemotherapy, n (%) 25 (10Æ4)
Low baseline albumin <35 g/dl, n (%)§ 54 (28Æ6)
High alkaline phosphatase
>250 IU/l, n (%)–
7 (3Æ1)
BSA, body surface area; GFR, glomerular filtration rate; IPI, Interna-
tional Prognostic Index; REAL, Revised European American Lym-
phoma; SD, standard deviation.
*n = 234.
 n = 237.
à<60 d prior to start of chemotherapy or ongoing infectious comor-
bidity.
§n = 189.
–n = 227.
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European Organisation for Research and Treatment of Cancer
(EORTC) Elderly Guidelines recommend primary prophylaxis
with CSF for all elderly patients receiving curative CHOP-like
chemotherapy (Repetto et al, 2003). Although many of the
other patient risk factors identified in this study do not
necessarily reflect risk factors highlighted in the guidelines, it is
important to recognise that the EORTC guidelines (Aapro
et al, 2006) are based on a literature review of studies across
tumour types and are not specific for NHL.
The increased risk for cycle 1 FN associated with age and low
baseline albumin, and the protective effects of CSF prophy-
laxis, are consistent with data from retrospective studies
specific to NHL patients (Lyman & Delgado, 2003; Rabinowitz
et al, 2006; Teegala et al, 2007). An increased risk of FN in
patients with low serum albumin (Intragumtornchai et al,
2000) or higher cyclophosphamide dose (Voog et al, 2000) was
also reported in early prospective studies in this patient
population. Data on the potential relationship between prior
chemotherapy, weight or recent infection and the risk of cycle
1 FN in NHL is limited. However, a US nationwide prospective
cohort study of 3468 patients with solid tumours or lymphoma
identified prior chemotherapy and concurrent antibiotics as
risk factors for neutropenic complications in cycle 1. We
assume that antibiotics are not in themselves a risk factor for
FN, but that they are prescribed to patients who are perceived
to be at higher FN risk. Other risk factors identified in the US
study were the number of myelosuppressive agents, anthra-
cycline-based regimens, planned chemotherapy delivery >85%
of standard, cancer type, phenothiazines, abnormal alkaline
phosphatase, elevated bilirubin, low platelets, elevated glucose
Table II. Treatment characteristics.
Regimen n
Distribution
(%)
Primary CSF
prophylaxis
%à (n)
Other
CSF use*
%à (n)
Rituximab
administration
%à (n)
Total 240 100 27Æ5 (66) 28Æ8 (69) 81Æ7 (196)
CHOP-21-like  178 74Æ2 19Æ7 (35) 34Æ3 (61) 86Æ5 (154)
CHOP-14-like 41 17Æ1 75Æ6 (31) 9Æ8 (4) 65Æ9 (27)
ACVBP-like 9 3Æ8 66Æ7 (6) 33Æ3 (3) 77Æ8 (7)
Other regimens 12 5Æ0 66Æ7 (8) 8Æ3 (1) 66Æ7 (8)
ACVBP, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; CHOP, cyclo-
phosphamide, doxorubicin, vincristine and prednisone; CSF, colony-stimulating factor.
*Secondary prophylaxis or treatment.
 Includes six patients with a cycle length of 28 d.
àDenominator values for percentage calculations are the regimen n-values in column 2.
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Fig 1. Incidence of febrile neutropenia (FN) in cycle 1 and across all
cycles. Error bars represent 95% exact binomial confidence intervals.
ACVBP = doxorubicin, cyclophosphamide, vindesine, bleomycin, and
prednisone. CHOP = cyclophosphamide, doxorubicin, vincristine and
prednisone. Data taken from Pettengell et al, 2008b.
Table III. Logistic regression model for predicting cycle 1 FN occur-
rence*.
Variable
Odds
ratio 95% CI P-value
Age  2Æ20 1Æ21–4Æ01 0Æ010
Weightà 0Æ62 0Æ43–0Æ89 0Æ010
Previous chemotherapy§ 6Æ39 1Æ72–23Æ68 0Æ006
Planned cyclophosphamide dose§ 1Æ16 1Æ02–1Æ32 0Æ023
Planned cytarabine dose§ 1Æ06 0Æ98–1Æ16 0Æ151
Planned etoposide dose§ 1Æ59 1Æ20–2Æ11 0Æ001
CSF before an event occurred– 0Æ18 0Æ03–0Æ94 0Æ042
Baseline albumin low** 4Æ76 1Æ35–16Æ71 0Æ015
Baseline albumin missing** 0Æ52 0Æ09–2Æ99 0Æ464
Recent infection   3Æ07 0Æ99–9Æ52 0Æ052
CI, confidence interval; CSF, colony-stimulating factor.
*Number of observations = 240, Wald v2 = 26Æ59, prob > v2 = 0Æ003,
log pseudolikelihood = )52Æ41.
 Per additional 10 years of age.
àPer additional 10 kg body weight.
§Planned doses in mg/m2 body surface area; per additional 50 mg/m2.
–Myelopoietic growth factor use before a FN occurred in cycle 1.
**Baseline albumin <35 g/dl, missing category introduced to avoid loss
of observations (sensitivity analyses did not reveal any relevant dis-
tortions with the use of this technique).
  During 60 d prior to chemotherapy or ongoing infectious comor-
bidity.
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and reduced GFR, whereas CSF prophylaxis was protective
(Lyman et al, 2006). Results from a subset of older patients
from the same registry (n = 1378) supported some of these
findings and additionally highlighted chemotherapy regimens
containing cyclophosphamide, etoposide or ifosfamide as
increasing the risk of early neutropenic events (Shayne et al,
2007a). Overall, the findings of the US prospective study
(Lyman et al, 2006; Shayne et al, 2007a) and the present study
were generally consistent and differences observed may be
related to the patient populations studied, treatment regimens
and sample size.
It is noteworthy that increasing planned chemotherapy dose
was predictive of FN in our model, in keeping with a
previously published model (Voog et al, 2000) and a recent
validated risk model that found that regimens containing
cyclophosphamide, etoposide or ifosfamide were associated
with an increased risk of early neutropenic events (Shayne
et al, 2007a). In our model, planned cyclophosphamide use
also correlated with the use of other anti-malignant agents,
which could potentially mask the contribution of these other
agents to the neutropenic potential of the chemotherapy
regimen. Planned etoposide dose was identified as a significant
predictor of cycle 1 FN; however, very few patients received
this agent. Similarly, risk estimates for recent infection were
based on a small number of observations (11 patients) and
require careful interpretation. CSF primary prophylaxis had a
significant protective effect against cycle 1 FN. The protective
effects of CSF have been validated previously (Komrokji &
Lyman, 2004; Aapro et al, 2006; Smith et al, 2006).
The high number of patients correctly classified by the model
(80%) suggests that it may have potential clinical utility. The
model showed good ability to discriminate between patients at
risk from cycle 1 FN and those not at risk. Model test
characteristics were comparable to, or better than, values
published for other risk models of neutropenia (Morrison et al,
2001; Lyman & Delgado, 2003; Lyman et al, 2006; Rabinowitz
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Fig 2. Receiver operating characteristic (ROC) curve for the multi-
variate analysis of factors predicting cycle 1 febrile neutropenia. Area
under ROC curve = 0Æ86 (95% confidence interval 0Æ79–0Æ94).
Table IV. Estimated risk [%] of cycle 1 FN and
any cycle FN following R-CHOP treatment for
NHL (cycle length 3 weeks) in an 80 kg subject
(average weight of male subsample) according
to age and risk factor profile. Estimated risks for
a lower assigned weight (55 kg) are given in
parentheses.
Cycle/risk factors
Age, years; weight 80 kg (55 kg), [%]
35 45 55 65 75
Cycle 1
None 0 (1) 1 (2) 1 (4) 3 (8) 6 (16)
Previous CT 2 (5) 3 (10) 7 (21) 15 (36) 28 (55)
Low albumin* 1 (4) 3 (8) 6 (16) 11 (30) 22 (48)
Recent infection  1 (2) 2 (5) 4 (11) 8 (21) 16 (37)
Previous CT + low albumin* 7 (20) 15 (36) 27 (55) 45 (73) 64 (86)
Previous CT + low albumin* +
recent infection 
19 (44) 34 (63) 54 (79) 72 (89) 85 (95)
Any cycle
None 5 (14) 8 (23) 14 (35) 22 (49) 34 (63)
Previous CT 8 (22) 14 (34) 22 (48) 34 (62) 48 (75)
ANC/WBC lowà 17 (41) 27 (55) 40 (69) 55 (80) 68 (88)
Alkaline phosphatase highà 31 (60) 45 (73) 59 (83) 72 (90) 82 (94)
CV comorbidity 11 (30) 19 (43) 29 (57) 42 (71) 57 (81)
Recent infection  14 (35) 23 (49) 35 (64) 49 (76) 63 (85)
ANC/WBC lowà + CV comorbidity 35 (64) 49 (76) 63 (85) 75 (91) 85 (95)
ANC/WBC lowà + CV comorbidity +
recent infection 
64 (85) 76 (91) 85 (95) 91 (97) 95 (98)
ANC, absolute neutrophil count; CT, chemotherapy; CV, cardiovascular; WBC, white blood cell
count.
*Baseline albumin <35 g/l.
 During 60 d prior to treatment.
àBaseline ANC <3Æ0 · 109/l or WBC <5Æ0 · 109/l; baseline alkaline phosphatase >250 IU/ml.
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et al, 2006; Shayne et al, 2007a,b). The 98% negative predictive
value showed that the model successfully identified patients at
low risk of developing FN. The 28% positive predictive value
(PPV) indicated that the model identified as high risk some
patients who did not ultimately have a cycle 1 FN event. While
a higher PPV is desirable, it should be remembered that the
PPV in this setting was partially driven by a low absolute
frequency of cycle 1 FN events and that not every patient who is
at high risk of FN will actually experience FN.
The potential clinical utility of the model was explored by
applying our dataset to hypothetical scenarios of NHL patients
and estimating the risk of developing FN in cycle 1 or any
cycle. Whilst the presence of some risk factors alone (e.g. low
baseline albumin) did not predict a high risk of FN, a
combination of risk factors increased the predicted risk for
developing cycle 1 FN substantially. In addition, patient
characteristics of older age or lower weight increased the
predicted risk for developing cycle 1 FN for any of the given
risk factor scenarios.
Owing to the sample size, the relatively infrequent occur-
rence of cycle 1 FN (9%) and the high number of covariates
used, the logistic regression model generated has some
potential limitations in its ability to correctly assess the impact
of rare risk factors and there is the possibility of artefacts. This
caveat particularly applies to the effects of some comorbidities
and baseline laboratory abnormalities. The standard approach
to randomly split the study dataset into a training dataset (on
which the model is estimated) and a test dataset (on which the
model is validated) was considered to be inefficient for the
same reasons. Ten-fold cross-validation has been shown to be
superior in small datasets (Goutte, 1997) and showed favour-
able results in the present case. However, additional validation
in an independent data set from a different population is
clearly required.
The any cycle model correctly classified 76% of patients, and
the test characteristics were comparable to a recent model of
risk for severe or febrile neutropenia across four cycles of
chemotherapy (Shayne et al, 2007b). The findings of the any
cycle model were similar to those observed with the cycle 1
model, with older age and increasing chemotherapy dose
identified as clinically relevant predictors of FN and prophy-
lactic CSF use and higher weight identified as being protective.
Although the use of a dose-dense regimen appeared predictive
of FN it did not attain statistical significance, which is probably
because most patients (76%) treated with dose-dense regimens
received CSF support. In addition, dose reductions and dose
delays before an event occurred had a significant protective
effect against FN. However, the practice of reducing or
delaying chemotherapy treatment in response to CIN and
FN has been questioned (Dale et al, 2003; Schwenkglenks et al,
2006), as decreased dose intensity has been associated with
increased morbidity and mortality (Kwak et al, 1990; Lepage
et al, 1993; Bonadonna et al, 1995; Budman et al, 1998; Bosly
et al, 2008; Pettengell et al, 2008a). Cardiac comorbidity was
also identified as a risk factor for any cycle FN, which is
consistent with current treatment guidelines (Aapro et al,
2006).
In summary, this study describes a prospective multivariate
risk model that was able to identify clinically relevant factors
that were predictive or protective of cycle 1 FN and correctly
identify a high proportion of patients at risk of first cycle FN.
Our model, together with treatment guidelines, may rationalise
the clinical decision of whether to support patients with CSF
primary prophylaxis based on their risk factor profile. Further
validation is required.
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Dear Editor,
Reductions in average relative chemotherapy dose intensity
(ARDI; i.e. administered compared with planned) compro-
mise patient outcomes [3], and a recent Belgian study
showed that survival for non-Hodgkin lymphoma (NHL)
patients receiving CHOP-21 was reduced when ARDI fell
below 90% [2]. We support these findings with similar data
from the UK Audit of Lymphoma Patients (n=78 patients
who received CHOP-21 chemotherapy in 1999–2000) and
from the combined Belgian and UK data (n=289) [4].
Patient, disease and treatment characteristics were similar
between the two studies, except that the UK patients were
younger (mean age ± SD was 55±15 years versus 63±
14 years) and fewer UK patients received colony stimulating
factor (CSF). First cycle CSF use was 4% in the UK study
compared to 25% in the Belgian study. During an average
time to death or censoring of 72 months, 35% of patients in
the UK study died. In the Belgian study, the average
observation time was 30 months, during which 31% of
patients died. After adjusting for the higher mean age of the
Belgian patients, Kaplan–Meier survival functions were
similar between the two populations (log-rank test stratified
by 10-year age groups, p=0.38).
Kaplan–Meier plots for patients with >90% ARDI versus
≤90% ARDI showed reduced survival for the patients with
≤90% ARDI (Fig. 1). A trend towards reduced survival was
apparent in the UK dataset alone (Fig. 1a; log-rank test-
based p=0.090). For the combined dataset, the effect was
statistically significant (p<0.001; Fig. 1b), as for the
Belgian data alone [2].
Potential predictors of reduced survival were assessed
using an extended Cox proportional hazards regression
model with robust standard errors allowing for clustering
by centre. Using the UK dataset, reduced survival was
significantly associated with a higher Ann Arbor disease
stage (hazard ratio (HR) at treatment initiation 2.59 per
stage increase by 1, 95% CI 1.45–4.66, p=0.001) and
showed a trend towards association with age (HR 1.02 per
year of age, CI 1.00–1.04, p=0.058) and RDI≤90% (HR
1.42, CI 0.88–2.28, p=0.146). Using the combined dataset,
reduced survival was associated with more advanced
disease stage (HR 2.00, CI 1.44–2.77, p<0.001), age (HR
1.03, 95% CI 1.01–1.05, p=0.002) and RDI≤90% (HR
1.77, CI 1.12–2.79, p=0.014). In both models, the strength
of the association with disease stage decreased over time.
Approximately 23% and 30% of UK and Belgian
patients, respectively, received ARDI≤90% and were,
therefore, at risk of reduced survival. There are many
factors that result in a decision to reduce or delay che-
motherapy, including local institutional practice. Particular-
ly relevant is the higher proportion of elderly patients in the
Belgian dataset; elderly patients are at high FN risk [1] and
often receive lower doses of chemotherapy [3]. Despite this
common practice, dose-dense CHOP-14 chemotherapy
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supported with G-CSF has been shown to be efficacious and
well tolerated in both young and elderly NHL patients [5, 6].
This study highlights the potential impact of receiving
ARDI≤90% on survival. While further investigation is
needed, delivering full chemotherapy dose intensity
remains an important goal in NHL patients who receive
CHOP-21 chemotherapy.
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The Prospective Oral Mucositis Audit: relationship of severe oral mucositis
with clinical and medical resource use outcomes in patients receiving
high-dose melphalan or BEAM-conditioning chemotherapy and
autologous SCT
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The Prospective Oral Mucositis Audit was an observa-
tional study in 197 patients with multiple myeloma (MM)
or non-Hodgkin’s lymphoma (NHL) undergoing, respec-
tively, high-dose melphalan or BEAM chemotherapy and
autologous SCT at 25 European centres. We evaluated
the relationship between severe oral mucositis (SOM;
WHO Oral Toxicity Scale grade 3–4) and local and
systemic clinical sequelae and medical resource use. SOM
occurred in 44% of patients. The duration of SOM (mean
5.3 days) correlated with time to neutrophil engraftment.
The following parameters increased gradiently with
maximum grade of oral mucositis: duration of pain score
X4, opioid use, dysphagia score X4, total parenteral
nutrition (TPN) use, incidence and/or duration of fever
and infection, and duration of antibiotic use. SOM
increased the duration of TPN use by 2.7 days
(Po0.001), opioids by 4.6 days (Po0.001), and anti-
biotics by 2.4 days (P¼ 0.045). SOM prolonged hospital
stay by 2.3 days (P¼ 0.013) in MM patients, but not in
NHL patients (who tended to have a longer hospital stay).
In conclusion, this analysis of prospectively collected
observational data provides important insight into the
scope and impact of SOM in the European transplant
setting.
Bone Marrow Transplantation advance online publication,
8 September 2008; doi:10.1038/bmt.2008.299
Keywords: oral mucositis; multiple myeloma; non-
Hodgkin’s lymphoma; high-dose chemotherapy; medical
resource use
Introduction
Oral mucositis (OM) is a very common debilitating adverse
event in patients receiving high-dose chemotherapy and
SCT,1 and results from damage to both epithelial and
submucosal tissues by the conditioning regimen.2 Clinical
manifestations of OM include signs and symptoms of an
inflammatory process, ranging from mild erythema, oede-
ma and soreness to extreme pain and ulceration. Severe
OM interferes with daily activities such as speaking, eating
and swallowing and has a negative impact on quality of
life.3,4 It can lead to dehydration, malnutrition and serious
infections5–8 and has been linked to inferior overall survival
(P¼ 0.002) after SCT.6
Several US-based analyses from various cancer settings
have demonstrated that severe OM increases healthcare
resource utilization by necessitating opioid analgesia, anti-
infective treatment, total parenteral nutrition (TPN) and
subsequently prolonging hospitalization.3,5,8,9 However,
medical resource use in relation to OM has not been
systematically assessed in the European SCT setting,
although a recently published overview provided insights
in the management of OM in European transplantation
centres.10
The Prospective Oral Mucositis Audit (POMA), con-
ducted by our group in 25 centres across 13 European
countries, was the first multi-country audit study with OMReceived 24 April 2008; revised 17 July 2008; accepted 19 July 2008
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occurrence as the primary objective. The first part of the
analysis (described in our initial paper) revealed a high
incidence of severe (World Health Organization (WHO)
oral toxicity scale grade 3–4)11 OM (44%) in patients with
multiple myeloma (MM) or non-Hodgkin’s lymphoma
(NHL) who underwent high-dose dose melphalan or
BEAM conditioning, respectively and autologous SCT.1
Severe OM risk and/or duration were significantly asso-
ciated with higher chemotherapy dose per kg body weight
and poor performance status, but in contrast to some
previous reports they were not related to age.
The POMA study also aimed to evaluate the clinical
sequelae of OM, including pain, dysphagia, fever and
infection, and to examine its impact on the use of
healthcare resources, including TPN, opioids and anti-
biotics, and duration of hospitalization. We present here
the results of these analyses.
Patients and methods
Study design and patient population
The POMA design has been described previously.1 In
brief, this prospective, observational audit recruited 197
adult patients with MM or NHL who received high-
dose melphalan (200mg/m2; MM patients) or BEAM
(carmustine 300mg/m2, etoposide 800mg/m2, cytarabine
800–1600mg/m2 and melphalan 140mg/m2; NHL patients)
conditioning chemotherapy followed by autologous SCT.
Exclusion criteria were previous SCT/BMT, palifermin
administration and presence of oral abnormalities at
baseline. Prophylaxis and treatment for OM and its clinical
sequelae were according to local clinical practice. Ethical
approval was obtained according to country-specific
requirements and all patients provided written informed
consent.
Patients were selected from European transplant units,
which had a history of reporting patients to the European
Society for Bone and Marrow Transplantation registry.
Centres were selected in which patients received autografts
as inpatients to monitor ‘mucositis’ accurately. Centres
were selected to represent a wide spectrum of European
countries and to allow training of nurses to be a practical
proposition.
Study assessments and data collection
Data collection included baseline demographic and medical
characteristics and type and dosage of conditioning
chemotherapy. OM assessments were conducted daily from
day 1 of conditioning chemotherapy until 30 days post
transplantation or hospital discharge (whichever occurred
first), using the five-point WHO oral toxicity scale (grade 1:
soreness and erythema, no further symptoms; grade 2:
ulcers present, but solid diet possible; grade 3: only liquids
can be swallowed; grade 4: oral alimentation impossible).
To achieve consistent high-quality OM assessment, on-site
nurse assessors and physicians underwent an intensive
training programme.12Ulcerative OM was defined as WHO
scale score 2–4 and severe OM as WHO scale score 3–4.
Specific 10-point scales were used to record local signs and
symptoms of severe OM (0¼no symptoms present;
10¼worst possible symptoms, as judged by patients).
Body temperature was recorded on the daily OM assess-
ment forms. Time to neutrophil engraftment (40.5 109/l)
was retrieved from the European Society for Bone and
Marrow Transplantation Promise database. Information
on infections and use of medical resources, including
medications used for OM prophylaxis and treatment was
obtained from the study sites. Medication categories
included mouthwashes, opioid analgesics, antibiotics, anti-
fungals, antivirals and other medications. These categories
were not prospectively defined and were therefore open to
interpretation by site staff. However, drug names were
requested for verification purposes (except in the case of
mouthwashes, as local preparations were often used). No
on-site monitoring was performed for this study.
Statistical methodology
Clinical end points included in this analysis were: WHO
oral toxicity scale score; duration of pain score X4, and
dysphagia score X4; incidence and duration of fever
(X38.0 1C), incidence of infection (clinically defined or
microbiologically confirmed) and of microbiologically
confirmed bacterial infection before day 30 post transplant-
ation, and time to neutrophil engraftment. Medical
resource utilization end points were duration of TPN,
opioid analgesic and antibiotic use and duration of
hospitalization.
The WHO scoring system was chosen because most
European transplant centres were familiar with this
instrument based on a survey by the nurses’ group of the
European Society for Bone and Marrow Transplantation.10
Missing WHO scale and pain score values during the
audit period were interpolated and missing values at
the beginning or end of the audit period extrapolated. For
the purpose of longitudinal assessments, a grade of 0 was
also imputed after patient discharge and fever and
dysphagia were assumed to be absent after patient
discharge. Temporal patterns were assessed by plotting
mean daily WHO scale-based OM scores and applicable
symptom-specific scores over the audit period. The propor-
tion of patients with fever was plotted in a similar way.
Using univariate analyses, associations of interest
were assessed using the w2 test, the non-parametric
Mann–Whitney U-test or the Spearman’s correlation
coefficient and its P-value, as appropriate. Multivariate
Poisson regression was used to further assess the impact of
severe OM on the duration of hospitalization. Parameters
that were explored as potential determinants of length of
hospital stay included baseline characteristics (age, sex,
weight, height, body surface area, Eastern Cooperative
Oncology Group (ECOG) performance status, type and
dosage of chemotherapy), time to neutrophil engraftment,
as well as infection-related parameters (incidence and
duration of fever and incidence of infection and micro-
biologically confirmed bacterial infection before day 30
post transplantation—which would be difficult to interpret
in models of OM occurrence).
Random effects modelling was used to assess possible
distortions of the main study results by centre effects.
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Poisson regression used generalized estimation equations
(GEE)-based robust s.e. estimates to allow for clustering by
study centre. Statistical analyses were performed using the
STATA/SE version 9 statistical software package. Statis-
tical tests were two-sided at the 5% significance level. Two-
sided 95% confidence intervals are shown.
Results
Study population
Patient baseline characteristics and conditioning chemo-
therapy doses for the 197 evaluable patients enrolled into
POMA (109 patients (55. 3%) with MM and 88 (44.7%)
with NHL) are summarized in Table 1. Mean recruitment
per centre±s.d. was 7.9±4.8 patients (range, 1–18). In the
MM group, the mean age was higher and there were fewer
women, consistent with the epidemiology of this disease.
The audit period lasted (mean±s.d.) 19.8±4.5 days in the
MM group and 22.4±3.7 days in the NHL group. The time
from first chemotherapy administration to transplantation
was longer in the NHL group than in the MM group
(median 7 vs 3 days), as BEAM is typically administered
over 5 days and high-dose melphalan over 1–2 days.
Patients received various types of OM prophylaxis,
including mouthwashes (78% of patients), antibiotics
(36%), antifungals (54%) and antivirals (44%), according
to local practice. The most frequently used antifungal
substance was fluconazole, followed by itraconazole,
systemic or local amphotericin B, and nystatin. Antivirals
were aciclovir or valaciclovir.
Evolution of OM
A total of 87 (44.2%). of 197 patients experienced severe
OM (46% in patients with MM and 42% in patients with
NHL), with a mean duration of 5.3±3.2 days: there were
no relevant differences between MM and NHL patients
with regard to these end points. A significant amount of
variation between centres with respect to these end points
was noted but random effects modelling yielded no
indication of a related distortion of the overall results.
The temporal relationship of WHO scale score with pain
and dysphagia scores, fever and neutrophil engraftment is
shown in Figure 1. The median onset of ulcerative OM and
of severe OM was on days 11 and 12, respectively, after the
start of conditioning chemotherapy. This coincided with
median onset of fever, infection and microbiologically
confirmed bacterial infection, both in patients with and in
patients without severe OM. The peak level of discomfort
was experienced on days 12–13 and this coincided with the
beginning of neutrophil engraftment (Figure 1). The
relationship of maximum grade of OM and clinical and
healthcare resource outcomes is summarized in Table 2.
Pain and opioid use
Not surprisingly, the duration of pain score X4 increased
gradiently with the maximum WHO OM scale score
(Po0.001), reaching a mean duration of 6.5 days in
patients with WHO grade 4 OM. Opioid analgesic use also
increased across the OM grades (Po0.001), patients with
Table 1 Patient demographics, baseline medical characteristics and treatment regimens, mean±s.d. (range) except where indicated
Multiple myeloma Non-Hodgkin’s lymphoma
n Observed value n Observed value
Age (years) 109 56.8 (39–73) 88 50.0 (18–69)
Female sex, n (%) 109 40 (36.7) 88 44 (50.0)
BSA 108 1.9 (1.4–2.4) 88 1.8 (1.3–2.7)
ECOG status, n (%)
0 59 (55.1) 67 (76.1)
1 42 (39.3) 16 (18.2)
2 5 (4.7) 5 (5.7)
3 1 (0.9) 0 (0.0)
Melphalan dose, mg/m2 BSAa 105 196±11 (136–219) 85 137 (115–151)
Carmustine, mg/m2 BSAa,b — 85 290±35 (0–322)
Etoposide, mg/m2 BSAa — 84 835±201 (598–1615)
Cytarabine, mg/m2 BSAa — 83 1388±330 (735–1720)
Observation time, median days (range) 109 19 (4–33) 88 22 (15–39)
Abbreviations: BSA¼ body surface area; ECOG¼Eastern Cooperative Oncology Group.
aDose actually administered.
bCarmustine was omitted from the conditioning regimen in one non-Hodgkin’s lymphoma patient.
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Figure 1 Evolution of mean WHO oral toxicity scale, pain and dysphagia
scores and proportions of patients with fever and neutrophil engraftment.
This assumes a standardized observation time of 39 days and zero score
values and proportions after the patients’ individual audit periods. Based
on n¼ 197 patients (193 with engraftment data).
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severe OM requiring an additional 4.6 days of opioid use
(Po0.001) compared with those without severe OM
(Table 2).
Dysphagia and TPN use
The duration of dysphagia score X4 increased with
increasing maximum WHO OM scale score (Po0.001),
reaching a mean duration of 8.4 days in patients with WHO
grade 4 OM. Duration of use of TPN (averaged across all
patients including those who did not receive TPN) also
increased across OM grades (Table 2), patients with severe
OM receiving an additional 2.7 days of TPN compared
with those without severe OM; (Po0.001). The incidence of
TPN use ranged from 19% in patients with no OM to 59%
in patients with WHO grade 4 OM. It was 35% across all
patients.
Fever and antibiotic use
Fever, infection and microbiologically confirmed infection,
increased with increasing grade of OM (Table 2). Compar-
ison of patients with and without severe OM showed that
patients with severe OM had a higher incidence of fever (68
vs 47% of patients; difference 21%; P¼ 0.004), infection
(42 vs 24%; P¼ 0.013) and microbiologically confirmed
bacterial infection (27 vs 12%; P¼ 0.013), and a longer
duration of fever (4.2 vs 3.0 days; P¼ 0.033). The duration
of severe OM (in patients who developed severe OM)
mostly showed the same associations, but it was not
significantly associated with the incidence of infection or of
microbiologically confirmed bacterial infection (data not
shown).
Combined duration of antibiotic use with prophylactic
and therapeutic intent also increased across OM grades
(Table 2), patients with severe OM receiving an additional
2.4 days of antibiotics (P¼ 0.045) compared with those
without severe OM.
Neutrophil engraftment
Time to neutrophil engraftment did not show any clear
correlation with the maximum grade of OM (Table 2) or
severe OM incidence, but it was positively correlated with
the duration of severe OM (Spearman’s correlation
coefficient 0.27; P¼ 0.012). This observation was confirmed
when time to neutrophil engraftment was tentatively
allowed as an additional covariate in the multivariate
analysis of severe OM duration (Po0.001), as noted in our
earlier analysis.1
Length of hospital stay
Length of hospital stay increased with increasing severity of
OM in patients with MM, ranging from 17.0±5.4 days in
patients with no OM to 21.5±3.7 days in patients with
grade 4 OM, with severe OM prolonging hospital stay by
2.3 days (P¼ 0.013). However this trend was less clear in
patients with NHL, who tended to have a longer hospital
stay than patients with MM (Table 2).
Multivariate Poisson regression analysis showed that
higher age, higher baseline Eastern Cooperative Oncology
Group performance status, longer duration of severe OM,
longer time from start of conditioning to transplantation
and longer time from transplantation to neutrophil
engraftment were associated with significantly longer
hospitalization (Table 3). The impact of duration of severe
OM on duration of hospitalization was attenuated by both
time to transplantation and time to neutrophil engraftment
(Table 3) (indicating that the effect of duration of severe
OM on hospital stay is reduced if hospitalization is
prolonged anyway). When indicators of fever or infection
were added to the model, the effect of severe OM duration
Table 2 Relationship between maximum grade of OM and clinical and health resource outcomes
Outcome Maximum WHO scale score (no. of patients)a Pb
0 (n¼ 26) 1 (n¼ 45) 2 (n¼ 39) 3 (n¼ 60) 4 (n¼ 27)
Clinical end pointsc
Pain score X4, days 0.1±0.3 0.9±1.9 1.5±2.3 5.2±4.0 6.5±3.6 o0.001
Dysphagia score X4, days 1.1±2.5 1.1±2.5 2.4±3.3 6.4±3.8 8.4±3.8 o0.001
Fever X38 1C, no. of patients (%) 8 (30.8) 21 (46.7) 23 (59.0) 38 (63.3) 21 (77.7) o0.001
Fever X38 1C, days 0.8±1.8 1.5±2.3 1.7±2.0 2.5±3.2 3.6±3.5 o0.001
Infection, no. of patients (%)d 7 (29.2) 10 (23.8) 7 (20.0) 21 (42.9) 7 (38.9) 0.075
Microbiologically confirmed infection,
no. of patients (%)d
2 (8.3) 7 (16.7) 3 (8.6) 11 (22.4) 7 (38.9) 0.011
Time to neutrophil engraftment, days 13.3±4.7 12.6±1.5 12.8±1.9 13.8±7.9 13.9±3.4 0.206
Health resource end points (duration, days)c
Opioid use 0.3±1.4 0.9±2.4 2.6±5.0 6.5±5.6 4.8±4.6 o0.001
TPN use 2.2±4.5 2.4±4.8 2.9±5.7 5.4±7.3 4.9±5.2 o0.001
Antibiotic use 4.8±6.4 5.5±7.7 8.7±8.4 9.1±9.5 8.3±7.2 o0.010
Length of hospital stay (MM) 17.0±5.4 19.8±3.9 19.7±4.7 21.5±4.5 21.5±3.7 0.008
Length of hospital stay (NHL) 21.1±3.0 23.1±4.1 24.1±5.2 22.2±3.5 23.8±3.3 0.086
Abbreviations: MM¼multiple myeloma; NHL¼non-Hodgkin’s lymphoma; TPN¼ total parenteral nutrition.
aPatient numbers shown differ slightly for both the infection variables (n¼ 24, 42, 35, 49, 18); time to engraftment (n¼ 26, 43, 39, 60, 27); and antibiotic use
(n¼ 26, 45, 39, 59, 27), on account of missing data.
b
w
2 test for incidence trend across grade of OM or Spearman’s correlation coefficient between duration and maximum grade of OM.
cDuration end points were calculated across all patients including those with 0 duration values.
dBefore 30 days post transplantation.
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was also attenuated. A similar pattern was seen using
incidence, instead of duration, of severe OM in the analysis.
Discussion
The initial analysis of the POMA findings provided the first
prospective, robust data on patterns and determinants of
severe OM in patients undergoing high-dose melphalan or
BEAM chemotherapy and autologous SCT.1 This second
analysis of data from this pan-European audit provides
new insights into the clinical sequelae of severe OM and
associated medical resource use.
Consistent with other observations,8,13 we found that
severe OM was closely related to development of fever,
with the incidence of fever being 21% higher and the
duration of fever 1.2 days longer, in those with severe OM.
Previous studies in the SCT setting have shown that the risk
of fever and/or febrile neutropenia (FN) increases with
increasing grade of OM.8,9 Moreover, the recombinant
growth factor palifermin, which protects the oral mucosa
from damage induced by myelotoxic-conditioning treat-
ment, was able to reduce the risk of FN in patients
undergoing SCT.14
The association of fever with oral mucositis has been
attributed to local and systemic infections, as disruption of
the mucosal barrier may provide an entry point for
pathogens.2,13 However, infection frequently cannot be
documented in febrile patients. An alternative hypothesis is
that fever may be a manifestation of the inflammatory
process that is induced by conditioning chemotherapy2,15–17
and driven by acute phase cytokines such as tumour
necrosis factor a (TNF-a) and interleukin 6 (IL-6).17,18
Mucositis itself is also a potential source of local and
systemic cytokines. These cytokines can induce sepsis-like
signs and symptoms when administered exogenously to
humans. Indeed, one study found that blood levels of TNF-
a and IL-6 were significantly correlated with changes in
body temperature in cancer patients who were administered
TNF.19
We found that severe OM duration was positively
correlated with time to neutrophil engraftment and that
engraftment coincided with peak OM scores (Figure 1).
This supports previous observations that healing of OM
coincides with neutrophil recovery.20–23 Although some
investigators have failed to find a link between OM and
neutropenia,5,24 Rapoport et al.25 noted that duration of
neutropenia was a risk factor for OM and the severity of
OM has been linked to the degree of neutropenia.26 Oral
neutrophil kinetic studies (using mouth rinses) in patients
recovering from profound neutropenia have demonstrated
that neutrophils are present in the tissues before peripheral
neutrophil counts recover,21,27,28 consistent with their
important role in mucosal defence and repair. A study in
the BMT setting found that neutrophil levels in mouth
rinses decreased to undetectable levels during the neutro-
penic period, but recovered 1–2 and 3–9 days before
peripheral neutrophil counts reached 0.1 and 1.0 109/l,
respectively, regardless of whether or not patients received
granulocyte-colony stimulating factor (G-CSF) support.21
A study in paediatric SCT patients found that the return of
neutrophils to the oral cavity marked the beginning of the
mucosal recovery phase. Moreover, the time span between
oral and peripheral neutrophil recovery was inversely
related to the number of infection-related febrile episodes
occurring after peripheral engraftment.27
Duration of severe OM was associated with the duration
of hospitalization, and development of severe OM pro-
longed the hospital stay by 2.3 days (P¼ 0.013) in MM
patients. However, fever and infection were cofactors in
prolonging hospitalization. Therefore, if severe OM is itself
a causative factor in fever and infection (Table 2), including
these covariates may lead to underestimation of the effect
of severe OM on duration of hospitalization, a major driver
of costs in this setting. Other factors influencing hospital
stay were age, baseline Eastern Cooperative Oncology
Table 3 Factors influencing duration of hospitalization (Poisson Model)
Duration of hospitalization
Coefficient (95% CI)a P
Ageb 0.004 (0.002 to 0.006) o0.001
Baseline ECOG statusc 0.052 (0.019 to 0.085) 0.002
Severe OM durationd 0.058 (0.024 to 0.091) 0.001
Time to transplantatione 0.058 (0.036 to 0.080) o0.001
Time to neutrophil engraftmentf 0.026 (0.014 to 0.038) o0.001
Interaction of time to transplantation and
severe OM duration
–0.005 (0.009 to –0.001) 0.015
Interaction of time to neutrophil engraftment
and severe OM duration
–0.002 (–0.004 to –0.000) 0.022
Constant 2.162 (1.869; 2.456) o0.001
aMultiplying the coefficients of Poisson Models by 100 yields a value approximating to percentage changes of the expected values of the response variable.
N¼ 191 on account of missing covariate values. One patient who died around the time of transplantation was hospitalized for only 3 days and one patient
with an outlying time from transplantation to neutrophil engraftment of 65 days was also excluded.
bPer additional year of age.
cPer score increase by 1.
dPer additional day.
ePer additional day from start of conditioning to transplantation.
fPer additional day from transplantation to neutrophil engraftment.
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Group status, time to transplantation and time to
neutrophil engraftment. Duration of use of TPN, opioids
and antibiotics also increased with increasing grade of OM,
patients with severe OM requiring an additional 2.7 days of
TPN, 4.6 days of opioids and 2.4 days of antibiotics. All
three associations are further supported by the very similar
temporal patterns of OM occurrence, pain, dysphagia and
fever (Figure 1).
Our findings are consistent with earlier data from the
United States. An earlier prospective, multicentre study in
blood or marrow transplant recipients (n¼ 92)8 and a
retrospective chart review in SCT recipients (n¼ 281)9
found that resource use and clinical outcomes, including
duration of hospitalization, were significantly correlated
with the severity of OM. A retrospective case–control study
in 24 patients who developed a-haemolytic streptococcal
bacteraemia following autologous BMT13 found that OM
prolonged hospital stay both independently and as a
cofactor associated with bacteraemia.
Systemic drug exposure was a key determinant of severe
OM risk in our previous analysis,1 in line with other
observations.29,30 Indeed, a recent study by a German
group found that patients treated with a melphalan dose
X70mg/m2 had a 23-fold increased risk of developing
mucositis (Po0.001) compared with those receiving lower
doses.30 Thus, we tentatively evaluated whether there was
an association between melphalan dose per kg body weight
and medical resource use, in MM patients only. No
relationship was found, indicating that the observed
associations of OM with medical resource use were not
directly on account of higher drug doses.
Changes in guidelines to prevent or treat OM have
recently been reviewed31 and include the use of cryotherapy
(ice-water or chips) during the infusion of high-dose
melphalan; however, the authors also state: ‘However,
additional and sustained efforts will be required to gain a
fuller understanding of the pathobiology, impact on overall
patient status, optimal therapeutic strategies, and improved
educational programs for health professionals, patients, and
caregivers’.
In conclusion, our analysis of prospectively collected
observational data has provided important insights into the
scope and impact of severe OM in patients undergoing SCT
in routine clinical practice in Europe. The correlation of
severe OM with serious systemic sequelae such as infection
and increased use of healthcare resources, together with the
adverse impact on patient quality of life, underlines the
need for effective measures for preventing OM. It is hoped
that our findings will help to guide the use of novel
preventive treatments.
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Summary
Objectives: Assessment of the prevalence, health care resource
use and cost of gastroesophageal reflux disease in Switzerland.
Methods: A population-based telephone survey was conducted
in German and French speaking Switzerland. Reflux cases were
defined using a questionnaire proposed by the German Gastro
League and answered additional questions on their personal
characteristics and resource use.
Results: 1274 out of 7222 participants were positively
screened. The prevalence of reflux disease in Swiss adults was
estimated at 17.6% (95% CI: 15.6%–19.7%) or 993000 indi-
viduals. Regular treatment with medication was reported by
38.0% of the reflux positive sample. Reflux-induced general
practitioner consultations during the last year were reported
by 25.9%. On average, there were 0.84 general practitioner
consultations, 0.19 specialist consultations, 0.08 gastroscopies
and 0.01 hospitalisations annually. Mean direct medical costs,
dominated by medication costs, were CHF 185 per patient-year
(95 % CI: CHF 140–230) or 0.5% of Switzerland’s total health
care expenditures. Total costs were CHF 234 (95% CI: CHF
185–284) per patient-year.
Conclusions: The prevalence of reflux disease in Switzerland is
similar to that in other industrialised countries. Reflux disease
causes considerable costs, in the medical system and at the so-
cietal level.
Keywords: Gastroesophageal reflux – Epidemiology – Economics –
Cost of illness – Switzerland.
Recent studies addressing the epidemiology of oesophageal
reflux disease have reported a tenfold increase in prevalence
during the last 30 years (El-Serag & Sonnenberg 1998). Du-
ring the same time span, reflux may have developed from a
problem mainly affecting males to one being equally distri-
buted between genders (Ter 2000).
Surveys in France, Great Britain, Italy, Sweden, and Ger-
many have shown that 18% to 40% of the populations of
these countries suffer from reflux symptoms (Kennedy et al.
1998; Rösch & Hotz 2000). U.S. prevalence figures are in the
same range (Spechler 1992; Locke et al. 1997). Quality of life
studies in patients with reflux disease show these to be se-
riously incapacitated (Rösch & Hotz 2000). Reflux disease is
associated with a risk of developing Barrett’s Esophagus
(BE), and of subsequently developing adenocarcinoma of
the oesophagus, with a very poor prognosis (Skinner et al.
1983).
The causes of the increase in reflux disease remain unclear.
Environmental factors such as stress, stimulus satiation, and
changes in dietary practices are discussed, as well as decrea-
sing infection rates with Helicobacter pylori and the intro-
duction of medications promoting reflux by relaxing the lo-
wer oesophageal sphincter (Lagergren et al. 2000).
The development of proton pump inhibitors (PPIs) has re-
volutionised the treatment of reflux disease and the ap-
proach to BE. PPIs allow for a continuous suppression of
gastric acid production, generally achieving a healing of oe-
sophagitis (Janknegt et al. 1999). In order to avoid recurren-
cies, costly continued treatment with this class of substances
is usually necessary (O’Connor et al. 2000).
The overall economic impact of reflux disease appears to be
significant. Cost of illness studies performed in the U.S. and
Great Britain reported annual costs of several hundred
Swiss francs per person (Levin et al. 1997; Eggleston et al.
1998). Information on the cost of illness of reflux disease in
Switzerland has not been published so far.
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Objectives
To address the epidemiology and economics of reflux di-
sease in Switzerland, with a principal focus on prevalence,
on the utilisation of health care resources, and on associated
costs.
Methods
Data collection
A population-based survey using computer-assisted tele-
phone interviews (CATIs) was conducted in November
2000. Interviewees were selected and interviews performed
by IPSO, Dübendorf, Switzerland, a company experienced
in the field of health-related survey research and collabora-
tor of several federal agencies including the Swiss Federal
Statistical Office. All interviewers were part-time employees
of IPSO. They had no medical training, but received a pro-
ject-specific introduction and continuous supervision by the
CATI lab’s leading staff.
The target population were persons domiciled in the
French- and German-speaking parts of Switzerland, aged 18
years or more. Interviewee selection was based on a two-
step random quota procedure using an address database list-
ing all Swisscom fixed telephone connections. A proportion
of three German speaking households to one French speak-
ing was maintained, reflecting the relative size of language
groups in the Swiss population. Within households, one per-
son was selected at random, but proceedings were modified
to fulfil age and gender quota corresponding to the mean
1998 permanent resident population (Bundesamt für Statis-
tik 1999). Households exclusively relying on mobile tele-
phones and persons living in institutions could not be inclu-
ded. At the time of the survey, fixed telephone coverage was
very high in Switzerland, with more than 4 200 000 fixed te-
lephone connections in a population of 7.164 Million (Bun-
desamt für Kommunikation 2000).
Calls were made Monday to Friday from 5 p.m. to 9 p.m.,
thus ensuring a high availability of professionally active as
well as other persons. 17654 telephone numbers were called.
In 646 cases, there was no contact after 10 calls, or the num-
ber belonged to a modem/fax device or a company, or it was
invalid. In 3592 cases, no person in the household met the
age and gender quota requirements. 1102 interviews could
not take place due to language problems or because the per-
son selected was too old or ill. Of the remaining 12314 per-
sons, 5092 (41%) refused or interrupted their interview.
7222 interviews (59%) were realised.
Screening was performed by recording reflux symptoms on
the basis of a questionnaire (Tab. 1) developed and applied by
the German Gastro League (Anonymous 2001). This instru-
ment is referring to the present, without explicitly specifying a
time span of observation. Focusing on heartburn and acid re-
gurgitation, it comprises eight easily understandable questions
divided into two sets of four. Persons answering at least one
question in each set positively are defined as reflux cases.
All positively screened interviewees were questioned in grea-
ter detail to assess their utilisation of medical resources and di-
rect medical costs. Absences from work were recorded to al-
low for the calculation of indirect costs. Additional sociode-
mographic, physiologic and anamnestic data were recorded to
be used in the analysis of prevalence (age, gender, language re-
gion), in the description of the characteristics of the reflux po-
sitive sample (age, gender, height, weight, smoking status, pre-
sence of asthma, percentage of women pregnant during the
observation period), and as potential influences on resource
use and cost (all afore mentioned, education, employment sta-
tus, household income, familial status, insurance status, urban
or rural character of place of domicile) to be taken into ac-
count in multivariate analysis (Schneeweiss & Sangha 2000).
Body mass index (BMI), smoking status, presence of asthma
and pregnancy have been previously reported to be positively
associated with the presence of reflux symptoms (Isolauri &
Laippala 1995; Mokhlesi et al. 2001). Screening interviews las-
ted about five, in-depth interviews about 12 minutes.
Cost analysis
Cost of illness studies usually divide costs into direct costs,
for which payments are made; indirect costs or losses of re-
sources; and intangible costs related to facts that are diffi-
cult to express in monetary terms, e.g., the consequences of
decreased quality of life (Rice 1994). Direct costs are esti-
mated as the product of the number of services performed
and their unit prices or charges. Following the human capital
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Table 1 Reflux checklist developed by the German Gastro League
Set 1: Questions 1–4
1. Do you have heartburn on several occasions during a month or 
do you experience burning in the throat?
2. Do you sometimes wake up at night with heartburn?
3. Do you get heartburn during sport or exertion?
4. Do you often notice acid regurgitation – for example after eating?
Set 2: Questions 5–8
5. Do you have heartburn more than twice a week or do you con-
tinually wake up during the night due to heartburn? 
6. Do you sometimes or regularly feel pain behind the breastbone 
that may radiate through to the back? 
7. Do you avoid certain foods or drinks for fear of heartburn? 
8. Do you regularly take medicines from the chemists shop against 
heartburn? 
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approach, indirect costs are viewed as the value of reduced
or lost productivity due to the disease in question. Intan-
gible costs are difficult to assess and, as in most studies, were
not included in our calculations.
Direct medical cost factors comprised outpatient costs
(consultation costs and outpatient endoscopy costs), hospi-
tal costs and medication costs. All expenditures on these re-
sources were taken into account independently of the payer
(patient, third-party, or state). In this sense, a societal pers-
pective of cost assessment was adopted.
All costs are indicated in their original currency and in Swiss
currency (CHF). On November 30, 2000, at the end of the
data collection period, CHF 1 equaled 0.57 US Dollars ($)
and 0.40 British Pounds (£).
Regional tariff lists (Kantonale Tarifvereinbarungen zwi-
schen Ärzten und Krankenkassen) valid in 1999 were used to
estimate mean consultation costs. Conservatively assuming
ordinary consultations without any particularities causing
extra charges resulted in an approximation of CHF 24.50 for
a consultation with a non-specialist as well as a specialist
physician. Using the same lists, outpatient endoscopies were
estimated to cost CHF 425 on average. It was assumed that,
in cases of a suspected diagnosis of reflux disease, complete
endoscopies of the oesophagus, stomach, and duodenum
were performed, but biopsies and other additional proce-
dures rarely needed.
A day on the general ward of a public hospital was reimbur-
sed with an intercantonal mean of CHF 320 in 1999 (Kon-
kordat der Schweizerischen Krankenversicherer 1999). Ad-
ditional public subsidies to the Swiss hospitals amounted to
CHF 4 700.5 Million in 1998 (Bundesamt für Statistik 2001).
Assuming these subsidies to support hospitals’ inpatient and
ambulatory expenditures proportionally, and dividing the
90% share of inpatient expenditures by the estimated num-
ber of 1998 hospital days, results in a mean subsidy of CHF
300 per day (Bundesamt für Statistik 2002). The sum of CHF
620 is used as an estimate of average daily hospitalisation
costs. This figure assumes that persons with a semi-private or
private complementary insurance are not excluded from the
benefits of public subsidies. Proceeding differently would be
difficult as the exact proportion of these persons is not
known (Bundesamt für Sozialversicherung 2000). Costs of
reflux-related operations were not assessed additionally, as
this would have raised a problem of double-counting.
Reflux-related medication costs during the 12 month period
preceding the survey were directly estimated by our inter-
viewees.
For the calculation of indirect costs, only the days off work
of persons with a full- or part-time work contract, and of
those self-employed or following a job-training were inclu-
ded. The costs of caring for relatives, of early retirement,
and of premature death should also be accounted for in
theory, but presumably can be neglected in the case of re-
flux. A one day absence from work was estimated to cost
CHF 230, on the basis of a population-level standardised
median salary of CHF 4988 as reported by the 1998 Salary
Structure Survey of the Swiss Federal Statistical Office
(Bundesamt für Statistik 1999).
Statistical methods
Sample weights were applied to correct for small deviations
from the age and gender quota requested, thus allowing for
population-adjusted prevalence estimates and ensuring
comparability of the characteristics of the positively scree-
ned individuals with population-level data from other
sources including the 1997 Swiss Health Survey (SHS ’97).
SHS ’97 results, originally covering persons aged 15 or older,
were recalculated by the Swiss Federal Statistical Office, to
meet the age range of this survey.
All statistical analyses were performed using SPSS 10.0®. To
analyse bivariate associations of categorical variables, odds
ratios (ORs) were calculated. In case of one continuous va-
riable, Mann-Whitney U tests and Kruskall-Wallis tests were
used, due to the skewed distributions observed (Glick &
Polsky 1999). Correlations of two continuous or ordinal va-
riables were assessed by Spearman’s correlation coefficient.
Two-tailed p = 0.05 was used as the level of statistical signifi-
cance. Confidence intervals (CIs) are given at the 95% level.
As there was no access to the SHS ’97 data at the individual
observation level, comparisons with these were not based on
statistical tests.
To further investigate significant bivariate associations and
correlations of potential influence factors on direct medical
costs, multivariate least squares regression on the logarithm
of direct medical costs was performed. Before taking the lo-
garithm, CHF 0.10 was added to all observations in order to
avoid undefined values.
Results
Prevalence of reflux disease and history of illness
The prevalence of reflux disease in the adult population was
17.6% (95% CI: 15.6%–19.7%), based on 1274 cases
among 7222 persons aged at least 18 years who were inter-
viewed. Using these data, the number of persons in Switzer-
land with reflux disease can be estimated at approximately
993000 (95% CI: 944000 – 1043000).
Of the persons interviewed, 5538 (76.7%) lived in the Ger-
man-speaking part of Switzerland, and 1683 (23.3%) lived
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in the French-speaking part. The proportion of the positi-
vely screened was 16.4% in the German-speaking part (907
persons) and 21.9% in the French-speaking part (368 per-
sons). This translates into a statistically significant OR of
1.34 (95% CI: 1.20–1.49).
There was a constant but moderate rise with age, from
11.7% in those aged 18 to 29 to a peak of 23.1% in persons
of age 70 to 79 (Tab. 2). The highest age group (80 and over)
reported a lower prevalence of 18.7%.
The proportion of the positively screened was 18.2% in the
women and 17.1 % in the men, corresponding to a non-si-
gnificant OR of 1.11 (95 % CI: 0.97–1.25).
Mean disease duration was 9.8 years (median 6 years). Strati-
fication by 10-year age groups shows mean values ranging
from 3.1 years in those aged 29 or younger to 14.2 years in
those aged 70–79 (Tab. 2). Here too, persons aged 80 or older
reported a lower figure. Medians followed a similar pattern.
Sociodemographic, physiologic and anamnestic variables
Table 3 shows characteristics of the persons identified to suf-
fer from reflux disease. These are contrasted to population
level estimates derived from all 7 222 interviews of this sur-
vey if available, or from the SHS ’97.
Mean age was slightly but significantly higher in the positi-
vely screened persons (p < 0.0005). The share of women was
2.0% higher in the positively screened group, which corres-
ponds to a non-significant OR of 1.11 (95% CI: 0.97–1.25).
Both absolute body weight and BMI results suggest a dis-
tinctly higher proportion of overweight persons in the reflux
positive compared to the general population. A history of
current or past smoking was reported by 48.6% of the reflux
positive persons, compared to 52.6% in the SHS ’97. Reflux
positive interviewees reported to suffer from asthma in 110
cases (8.6%).
Table 2 Prevalence and disease duration by 10–year age intervals
Age N (total) N (reflux positive) Prevalence Disease duration (years)
% (95 % CI) Mean ± standard deviation Median
All ages 7 222 1 274 17.6 (15.6–19.7) 9.8 ± 10.6 6
18–29 745 87 11.7 (9.4–14.0) 3.1 ± 2.7 2
30–39 1 438 211 14.7 (12.9–16.5) 6.2 ± 5.5 5
40–49 1 440 246 17.1 (15.2–19.0) 9.4 ± 8.1 8
50–59 1 263 249 19.7 (17.5–21.9) 9.9 ± 9.2 7
60–69 961 193 20.1 (17.6–22.6) 11.7 ± 11.2 8
70–79 736 170 23.1 (20.1–26.1) 14.2 ± 14.2 10
≥ 80 638 119 18.7 (15.7–21.7) 12.4 ± 15.5 5
Table 3 Characteristics of positively screened persons and population level estimates
Variable Positively screened Population aged Source of population-
persons (N = 1 274) 18 or older level estimate
Average value ± standard deviation or %
Age (years) 49.4 ± 17.3 46.7 ± 18.0 N = 7 222 a
Women (%) 53.4 51.8 N = 7 222 a
Height (cm) 170.0 ± 11.3 169.7 SGB ‘97 b
Weight (kg) 71.8 ± 14.7 69.8 SGB ‘97 b
BMI groups (%) c < 20 9.2 12.0 SGB ‘97 b
= 20, <25 46.0 51.8
= 25, <30 35.0 29.1
= 30 9.8 7.1
History of smoking (%) 48.6 52.6 SGB ‘97 b
Asthma (%) 8.6 3.1 SGB ‘97 b
Presence of pregnancy in 6.0 – not available
women aged 18 – 45 years (%)
a All interviewees of our telephone survey
b Swiss Federal Statistical Office, 1997 Swiss Health Survey. Reference: persons aged 18 or older. Standard deviations not available
c Unit of BMI: kg/m 2
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Utilisation of medical resources
Only 796 (62.4%) of the reflux cases reported to “do some-
thing against the disease”. Regular treatment with medica-
tion was reported by 458 (38.0%). Information on the names
of the drugs used was provided by 349 persons, of which 114
(32.6%) took prescription drugs. Combining these figures
lead to an estimate of 11.8% of the persons with reflux ta-
king prescription drugs (mainly PPIs) regularly.
Treatment by a general practitioner in the 12 months prece-
ding the survey was reported by 330 (25.9%) patients, who
saw their doctor 3.1 times on average (95% CI: 2.7–3.5, me-
dian 2). The maximum number of consultations due to re-
flux was 25. Specialists were consulted up to 12 times by 134
patients (10.6%), 1.8 times on average (95% CI: 1.6–2.1,
median 1.8). A history of gastroscopy was reported by 382
patients (30.0%). This procedure took place within the pre-
vious year in 95 patients (7.5%). A history of reflux-related
hospitalisation was reported by 55 persons (4.3%), and by
14 patients (1.1%) with reference to the previous year. Mean
duration of hospitalisation was 9.7 days (median 7). Hospi-
talisations during the year preceding the survey only lasted
6.3 days (median 4.8).
Mean consultation frequencies for all positively screened
persons and utilisation frequencies of other health care re-
sources are shown in Table 4. At this level, medians were 0
for all resource use variables, due to heavily right-skewed
distributions.
Reflux-related absences from work during the last 12
months were remembered by 48 persons (3.8% or 7.7% of
those being professionally active or on a job training). Mean
duration of absence from work was 5.6 (median 2.3) days,
which corresponds to 0.4 (median 0) days per year in the
professionally active, and to 0.2 (median 0) days per year in
all positively screened persons.
Costs of gastroesophageal reflux in Switzerland
Direct costs: The mean contribution of different cost para-
meters to reflux-associated direct medical costs is shown in
Table 5. Medians were CHF 0, due to heavily right-skewed
distributions. This was mirrored in the reflux-associated di-
rect medical costs themselves. These amounted to CHF 185
(95% CI: CHF 140–230) per year on average, and were
clearly dominated by medication costs, with hospital, endo-
scopy, and general practitioner costs being second to fourth
in importance.
Higher direct medical costs were weakly correlated with age
(Spearman’s correlation coefficient 0.16, p < 0.005) and di-
sease duration (Spearman’s correlation coefficient 0.07,
p = 0.013). Correlations with weight (0.01, p = 0.745) and
BMI (0.05, p = 0.092) were not statistically significant. There
was virtually no cost difference between men and women
(CHF 184 vs CHF 186, p = 0.835). Cost differences between
persons with and without a history of smoking (CHF 156 vs
CHF 213, p = 0.930), and between asthma patients and non-
asthma patients (CHF 217 vs CHF 182, p = 0.500) were not
statistically significant.
Higher costs in the French versus German speaking areas
(CHF 191 vs CHF 183) and in persons living in urban versus
rural surroundings (CHF 235 vs CHF 150) reached statisti-
cal significance (p = 0.018 and p = 0.020). The level of edu-
cation also had a significant effect on treatment costs
(p = 0.046). Persons having completed compulsory educa-
tion and/or a professional training incurred costs of CHF 203
per year, those with a high school diploma incurred costs of
CHF 121, and those with a technical school diploma or a uni-
versity degree costs of CHF 154. Costs of persons with sta-
tutory health insurance were CHF 187 per year on average,
whereas persons with an additional semi-private or private
insurance incurred costs of CHF 174 and CHF 228 per year,
respectively (p = 0.270). Correlation with houshold income
was negative, but weak and non-significant (Spearman’s cor-
relation coefficient -0.05, p = 0.165).
Multivariate least squares regression on the logarithm of di-
rect medical costs confirmed that all associations and corre-
lations found to be significant in bivariate analysis were also
significant or near-significant in regression, with their direc-
tions unchanged. Disease duration was the only exception.
Other potential influences did not reach p-values < 0.20. The
Table 4 Utilisation of medical services and absences from work due to reflux disease, per patient-year (N = 1 274)
Resource No. of patients using resource or Units consumed Rate/patient/year
being affected during reference period
Mean 95% CI
General practitioner consultations 330 (25.9%) 1 071 0.84 0.71–0.97
Specialist consultations 134 (10.6%) 245 0.19 0.15–0.23
Endoscopies 95 ( 7.5%) 95 0.08 0.06–0.09
Hospitalisations 14 ( 1.1%) 14 0.01 0.01–0.02
Hospital days – 91 0.07 0.01–0.13
Days off work 49 ( 3.8%) 272 0.21 0.12–0.30
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explanatory power of all possible models remained minimal,
with R-squared values consistently below 0.05. Table 6 shows
the final model.
Indirect costs: Calculation based on reflux-related days off
work as reported by our interview partners lead to an esti-
mate of mean indirect costs of CHF 49 (95% CI: CHF
28–70) per person-year for all reflux cases, and of CHF 90
(95% CI: CHF 52–128) per person-year in those professio-
nally active or on a job training. Medians were 0 in both
cases.
Total costs: Total costs summed up to CHF 234 (95% CI:
CHF 185–284) per person-year.
Extrapolation to the whole of Switzerland
Assuming 993000 Swiss persons with reflux disease lead to
an estimate of the total costs of reflux disease in Switzerland
of CHF 0.23 billion per year. Direct medical costs amounted
to CHF 0.18 billion per year.
According to the Swiss Federal Statistical Office, total
health care expenditures in Switzerland amounted to CHF
39.8 billion in 1998 (Bundesamt für Statistik 2001). Thus, the
direct medical costs of reflux disease account for approxi-
mately 0.5% of total Swiss health care expenditures.
Discussion
The main methodological issues to be addressed are the ad-
vantages and disadvantages of population-based data collec-
tion, the choice of risk score, and cost assessment.
Data collection: Any approach to the study of reflux disease
relying solely on medical records would necessarily unde-
restimate prevalence at the population-level and overesti-
mate resource use per person, as many of those affected do
not seek medical assistance. A population-based approach
to data collection is necessary. Thus, the distortions occur-
ring if non-representative samples of study participants are
recruited in physician’s offices can largely be avoided. In
addition, out-of-pocket expenses never showing up in me-
dical records can be accounted for. On the other hand, po-
pulation-based data collection has its own pitfalls, the most
important being limited quality of information, recall bias
and selection bias.
The most important potential reason of selection bias des-
pite correct sampling is non-response. Comparisons of face-
to-face, mailed and telephone surveys addressing health-re-
lated issues showed small differences between modes of ad-
ministration and small non-response effects with respect to
prevalence estimates (Marcus & Crane 1986; O’Toole et al.
1986). Non-response in telephone surveys was found to be
less content-oriented than in mailed surveys (Fowler et al.
2002). Also, bias due to different sociodemographic charac-
teristics of persons inaccessible by telephone affected re-
ports of illness and related use of services only marginally, if
the general population was addressed and if telephone co-
verage was at least 90% (Marcus & Crane 1986; Ford 1998).
It can be assumed that these preconditions were fulfilled in
Switzerland at the time of our data collection, when exclu-
sive use of mobile phones was still infrequent. Persons living
in institutions could not be included, which would be critical
in the study of a disease affecting the higher ages differen-
tially or directly causing institutionalisation. In the case of
reflux, it should be of minor importance. The overall risk of
relevant selection bias can be assumed to be relatively small
in this study.
Information quality clearly is a more critical problem. As-
sessments of health related issues and resource use by survey
methods are prone to error and recall bias. Comparisons
with medical records have revealed relevant potential short-
comings, notwithstanding the fact that the completeness and
correctness of medical record information is an issue in itself
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Table 5 Costs of reflux disease in Switzerland, per patient-year 
(N = 1274)
Resource Costs/patient/year (CHF)
Mean 95 % CI
General practitioner consultations 21 17–24
Specialist consultations 5 4–6
Endoscopies 32 26–38
Medication 84 63–104
Total ambulant costs 141 117–165
Hospital costs 44 8–80
Direct medical costs 185 140–230
Indirect costs 49 28–70
Total costs 234 185–284
Table 6 Multivariate least squares regression on the logarithm of direct
medical costs (N = 1 266 a)
F(5,1266) = 8.587 Prob > F = 0.000
R-squared = 0.033 Adjusted R-squared = 0.029
Covariates Coef. 95% CI
Age 0.024 0.012 0.035
German language region b – 0.764 – 1.188 – 0.340
Rural dwelling c – 0.478 – 0.865 – 0.091
Education:
High school d – 0.256 – 0.859 0.347
University or equivalentd – 0.679 – 1.189 – 0.168
Intercept 0.992 – 0.221 2.205
a N < 1 274 due to missing values
b Compared to French language region
c Compared to urban dwelling
d Compared to compulsory education and/or professional training
57Originalartikel l Original article
Soz.- Präventivmed. 49 (2004) 51–61
© Birkhäuser Verlag, Basel, 2004
(McKinnon et al. 1997). Studies of chronic conditions like lo-
wer back pain and asthma hint at a moderate underreporting
of medium to long term prevalence, in the range of 5–20%,
while forward telescoping of earlier events may partially
compensate for this effect (Carey et al. 1995; Mathiowetz &
Dipko 2000). Recall of resource use has been observed to
deteriorate seriously after 10 months, and up to 20% of in-
formation may be lost after one year (Brown & Adams
1992). Reports of the exact number of disease-specific and
overall physician consultations during the previous 12
months differed from medical record-based information in
up to 70% of cases, but similar rates of under- and overre-
porting greatly reduced overall error (McKinnon et al. 1997;
Mathiowetz & Dipko 2000). Hospitalisations and their
causes were well remembered, while the validity of reports
of drug use was judged more critically (Brown & Adams
1992). All modes of administration seem to be affected by
these problems in about the same way, despite some advan-
tages of face-to-face and telephone interviews in comparison
with mailed questionnaires (Marcus & Crane 1986; O’Toole
et al. 1986; McKinnon et al. 1997; Galobardes et al. 1998;
Brogger et al. 2002).
In summary, collection of health-related data in general po-
pulations using survey methods is an accepted, while not en-
tirely unproblematic alternative to medical record review
(Marcus & Crane 1986; Brown & Adams 1992). It was justi-
fied in this study as a medical record-based approach could
not have produced population-level estimates. Neverthe-
less, some measurement error and bias may be present in the
results. Reports of earlier studies indicate that this may have
induced an under- as well as an overestimation of some pa-
rameters, but probably no major distortions.
Choice of risk score: A variety of questionnaires have been
used to measure the presence of reflux disease. These were
designed to be used in self-reporting (Isolauri & Laippala
1995; Ledson et al. 1998), in face-to-face interviews with trai-
ned interviewers (Eggleston et al. 1999), or in physician in-
terviews (Klauser et al. 1990). Until today, no standard has
emerged, and results strongly depend on the reference per-
iods used, ranging from one day to one year (Isolauri &
Laippala 1995). All instruments address heartburn and acid
regurgitation, while in part considering additional symptoms
such as dysphagia, globus, nausea, belching, or chest-pain.
Validation is complicated by a lack of gold standard, as even
invasive procedures such as pH monitoring and gastroscopy
are of limited sensitivity and specifity (Johnsson et al. 1987;
Klauser et al. 1990). Only the instruments developed by An-
dersen et al. (1987) and Locke et al. (1994) and, to a certain
extent, the DIGEST instrument have been formally validat-
ed (Eggleston et al. 1999). All three are clearly too extended
to be used in a population-based screening study using CA-
TIs. Measures specifically designed or validated for use in a
CATI framework are not available. The questionnaire by
Locke et al. was used in a telephone setting once, but for
reassessment purposes only (Newton et al. 1999). Facing the
lack of a formally validated instrument suitable for this
study, we selected a measure which relied on easily under-
standable questions with good face value. It covered the
symptoms jointly addressed by all instruments proposed,
and it could be assessed by phone without problems, re-
nouncing highly elaborated formal definitions in favour of
interviewee compliance.
Cost assessment: Cost assessment can follow a top-down or
a bottom-up approach (Tolpin & Bentkover 1983). The lat-
ter derives healthcare costs from aggregated sources (e.g.,
national statistical records). Due to a lack of central data-
bases, this approach can hardly be adopted in Switzerland.
The bottom-up approach, which we used, determines re-
source use at the single patient level and multiplies per ca-
pita resources with the appropriate epidemiological figures
like prevalence or incidence. Using a population-based ap-
proach to derive these figures allows for a relatively high
degree of external validity. Assessment of unit costs, how-
ever, often has to be based on approximations. This is parti-
cularly true for Switzerland’s very decentralised health care
system.
Medication costs dominate medical resource costs in reflux
disease. Interviewees’ estimates of these costs are certainly
far from being exact. In diseases mainly requiring conti-
nuous medication, it would be more appropriate to ask for
the daily doses, to which public prescription prices could be
applied. Treatment of reflux disease, however, is in many
cases characterised by on demand medication, whose inten-
sity may be remembered in even less detail. Direct estimates
should be more reliable under such circumstances.
Epidemiologic results: Most of our epidemiologic results are
a confirmation of previous findings from other industrialised
countries. Our prevalence estimate of 17.6%, referring to
the adult population, is in the range to be expected from
many studies (Spechler 1992; Locke et al. 1997; Kennedy et
al. 1998; Rösch & Hotz 2000; Ter 2000). The findings of the
Domestic/International Gastroenterology Surveillance
Study (DIGEST), however, contradict our result (Eggleston
et al. 1999; Stanghellini 1999). Based on 5600 interviews in
10 industrialised countries, DIGEST found an overall pre-
valence of reflux-like symptoms of 7.7%, and a prevalence
in Switzerland of 4.8% (Stanghellini 1999). Several metho-
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dological differences contribute to the explanation of this
discrepancy: The Swiss DIGEST sample comprised 500 per-
sons only, living in some few urban agglomerations (Eggles-
ton et al. 1999). A reference period of three months was
used. Reflux symptoms had to reach a certain level of “rele-
vance” to be counted, and were not considered if other up-
per gastrointestinal (GI) symptoms were more prominent.
Total Swiss prevalence of relevant upper GI symptoms was
found to be 17.7% (Stanghellini 1999).
The observation of a significantly higher prevalence rate in
the French speaking part of Switzerland may be due to a real
epidemiologic difference or due to a higher awareness of re-
flux disease in this region.
A rise of reflux prevalence with age has been previously re-
ported (Isolauri & Laippala 1995; Eggleston et al. 1999).
Spechler (1992) even found a dramatic increase in those
over age 40. Our additional finding of a reduced prevalence
in the highest age group, which has not been described be-
fore, can be assumed to be an artefact. It possibly results
from a reduced awareness of reflux due to an increased pre-
sence of other, more threatening health problems. Disease
duration also rose with age, but had lower values in the 
highest age group. Recall bias may be an important factor
here. Nevertheless, our results suggest that disease duration
is limited in many cases, or at least that disease intensity of-
ten regresses to a level which is not remembered over pro-
longed periods of time. Reflux disease develops at all adult
ages. The absence of a gender gap in the reflux-positive
sample is consistent with the findings of several observatio-
nal studies (El-Serag & Sonnenberg 1998; Kennedy et al.
1998; Eggleston et al. 1999; Ter 2000).
Comparisons of our data with population-level estimates
from the SHS ‘97 (Table 3) may be affected by selection bias
in one or both data sources. If no relevant distortions of this
kind are assumed, our results support an association between
reflux and overweight, which is controversial in the litera-
ture, but confirmed by DIGEST (Isolauri & Laippala 1995;
Eggleston et al. 1999; Lagergren et al. 2000). Some studies re-
ported an increased prevalence of reflux disease in persons
with a history of smoking and, nearly undisputed, a negative
influence of smoking on disease severity (Isolauri & Laippala
1995; Pandolfino & Kahrilas 2000). Thus, the finding of a re-
duced number of smokers in the reflux-positive persons com-
pared to the SHS ‘97 estimate could potentially result from
an influence of reflux symptoms on smoking habits. The
asthma prevalence in the reflux-positive interviewees of
8.6% is best compared with an earlier report of a prevalence
of 6.7% in the adult Swiss population (Leuenberger 1995). A
positive association between reflux disease and asthma has
been reported earlier (Mokhlesi et al. 2001).
Our population-level estimate of 993 000 persons with reflux
disease in Switzerland is conservative as it does not include
persons under 18 years of age with reflux.
Cost results: Our cost estimates are seemingly low. While 
several of the methodological issues addressed above may
have contributed to this, the main reason lies in the fact that
we included all reflux-positive persons identified, unregard-
ing the question if they were medically treated or not. Dur-
ing the 12 months preceding their interview, only 26% of our
reflux positive sample reported a general practitioner
consultation due to this condition. Studies only including
persons undergoing medical treatment must yield higher re-
source use and cost estimates. This is the case in most re-
search addressing the economics of reflux disease (Viljakka
et al. 1997; Sonnenberg et al. 1999; Gerson et al. 2000). Eg-
gleston et al. (1998), e.g., refer to a period of initial medical
activity. They report costs in the range of £ 136 to £ 189 (CHF
341 to CHF 474) and a mean of 2.4 to 2.9 general practitio-
ner consultations during six months. We observed 3.1 con-
sultations per one year in those interviewees who reported
reflux-induced consultations. (Except by chance, these were
not in their initial treatment phases.) Levin et al. (1997)
found annual treatment costs in the range of $ 471 (CHF
826) in a U.S. managed care setting. Our results, referring to
a population with a distinctly lower mean intensity of disease
and being based on a different health care system, are com-
patible with these findings.
Most significant bivariate associations we found between di-
rect medical costs and possible influence variables (age, lan-
guage region, urban or rural dwelling, educational level)
were confirmed in regression analysis. Our observation of a
moderate rise of costs with age can be assumed to be of in-
direct nature. Longer disease duration in older persons may
be the true reason. Higher costs of reflux disease in the
French compared to the German language region probably
are a reflection of higher total health care costs (Frei & Tin-
turier 1996). An above-average density of health care provi-
ders may have contributed to the observation of higher costs
in urban areas. Despite their plausibility, the explanatory va-
lue of all influences identified is minimal. Treatment inten-
sity may largely be ruled by personal attitudes of the patients
and physicians involved, and chance may also have an im-
portant role. Other studies might try to find better explana-
tory variables than those we measured, to allow for a better
prediction of costs.
In addition, further methodological research should in greater
depth address the difficulties and relationship of medical re-
cord-based and survey-based collection of health-related data.
Optimised future study designs might combine the use of 
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survey methods for case identification and of medical record
review for the collection of resource use and additional data.
Epidemiologic, resource use and cost results demonstrate
that reflux disease is of considerable importance medically,
but also economically. Our estimate of reflux disease ac-
counting for approximately 0.5% of the total Swiss health
care expenditures has probably to be viewed as conserva-
tive, due to the implications of study design.
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Zusammenfassung
Epidemiologie und Kosten der gastroösophagealen Reflux-
krankheit in der Schweiz: eine bevölkerungsbasierte Studie
Fragestellung: Messung der Prävalenz, des medizinischen Res-
sourcenverbrauchs und der Kosten der gastroösophagealen
Refluxkrankheit in der Schweiz.
Methoden: In der deutschsprachigen und französischsprachi-
gen Schweiz wurde eine bevölkerungsrepräsentative Tele-
fonumfrage durchgeführt. Personen mit Reflux wurden an-
hand eines von der Deutschen Gastro-Liga vorgeschlagenen
Fragebogens identifiziert und beantworteten zusätzliche Fra-
gen zu ihren persönlichen Charakteristika und zum medizini-
schen Ressourcenverbrauch.
Ergebnisse: 1274 von 7222 TeilnehmerInnen wurden als Re-
fluxfälle definiert. Die Prävalenz der Refluxkrankheit unter
Schweizer Erwachsenen wurde auf 17.6% (95%-KI: 15.6%–
19.7%) oder 993000 Personen geschätzt. Eine regelmässige
medikamentöse Behandlung wurde von 38.0% dieser Perso-
nen angegeben. Durch Reflux bedingte Allgemeinarztkonsul-
tationen während des letzten Jahres wurden von 25.9%
berichtet. Im Durchschnitt betrug die Zahl der Allgemeinarzt-
konsultationen 0.84, die Zahl der Spezialistenkonsultationen
0.19, die Zahl der Gastroskopien 0.08 und die der Hospitalisa-
tionen 0.01 pro Patientenjahr. Die durchschnittlichen direkten
medizinischen Kosten wurden durch die Medikamentenkosten
dominiert und betrugen CHF 185 pro Patientenjahr (95%-KI:
CHF 140–230) oder 0.5% der gesamten Gesundheitsausgaben
der Schweiz. Die totalen Kosten beliefen sich auf CHF 234
(95%-KI: CHF 185–284) pro Patientenjahr.
Schlussfolgerungen: Die Prävalenz der gastroösophagealen
Refluxkrankheit in der Schweiz ähnelt der in anderen indus-
trialisierten Ländern beobachteten. Die Kosten der Reflux-
krankheit sind sowohl auf der medizinischen als auch auf der
gesellschaftlichen Ebene beträchtlich.
Résumé
Epidémiologie et coûts du reflux gastro-oesophagien 
en Suisse: une étude dans la population générale
Objectifs: Evaluation de la prévalence, de la consommation de
prestations médicales et des coûts du reflux gastro-oesopha-
gien en Suisse.
Méthodes: Une enquête téléphonique a été menée dans la
population générale en Suisse alémanique et Suisse romande.
Les cas de reflux on été identifiés en utilisant un questionnaire
proposé par la ligue allemande contre les maladies gastriques
et interrogés sur leurs caractéristiques personnelles et leur con-
sommation de prestations médicales.
Résultats: On a dépisté 1274 cas positifs sur 7222 participants.
La prévalence du reflux parmi les adultes en Suisse a été es-
timée à 17.6% (IC 95%: 15.6%–19.7%), correspondant à
993000 personnes. Un traitement médicamenteux a été suivi
par 38.0% des cas positifs, et 25.9% ont déclaré d’avoir con-
sulté leur médecin généraliste pour cause de reflux pendant
l’année précédente. En moyenne, on a dénombré 0.84 consul-
tations au cabinet généraliste, 0.19 consultations d’un spécial-
iste, 0.08 gastroscopies et 0.01 hospitalisations par personne-
année. Les coûts médicaux directs, dominés par les coûts
médicamenteux, se sont montés en moyenne à CHF 185 par
personne-année (IC 95%: CHF 140–CHF 230) ou à 0.5% des
dépenses de santé en Suisse. Les coûts totaux ont été de CHF
234 (IC 95%: CHF 185–CHF 284) par personne-année.
Conclusions: La prévalence du reflux gastro-oesophagien en
Suisse est comparable à celles des autres pays industrialisés. Le
reflux est à l’origine de coûts considérables au niveau du sys-
tème de santé et au niveau de la société.
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Abstract The aim of our study was to develop a mod-
eling framework suitable to quantify the incidence,
absolute number and economic impact of osteoporosis-
attributable hip, vertebral and distal forearm fractures,
with a particular focus on change over time, and with
application to the situation in Switzerland from 2000 to
2020. A Markov process model was developed and
analyzed by Monte Carlo simulation. A demographic
scenario provided by the Swiss Federal Statistical Office
and various Swiss and international data sources were
used as model inputs. Demographic and epidemiologic
input parameters were reproduced correctly, confirming
the internal validity of the model. The proportion of the
Swiss population aged 50 years or over will rise from
33.3% in 2000 to 41.3% in 2020. At the total population
level, osteoporosis-attributable incidence will rise from
1.16 to 1.54 per 1,000 person-years in the case of hip
fracture, from 3.28 to 4.18 per 1,000 person-years in the
case of radiographic vertebral fracture, and from 0.59 to
0.70 per 1,000 person-years in the case of distal forearm
fracture. Osteoporosis-attributable hip fracture numbers
will rise from 8,375 to 11,353, vertebral fracture numbers
will rise from 23,584 to 30,883, and distal forearm
fracture numbers will rise from 4,209 to 5,186. Popula-
tion-level osteoporosis-related direct medical inpatient
costs per year will rise from 713.4 million Swiss francs
(CHF) to CHF946.2 million. These figures correspond
to 1.6% and 2.2% of Swiss health care expenditures in
2000. The modeling framework described can be applied
to a wide variety of settings. It can be used to assess the
impact of new prevention, diagnostic and treatment
strategies. In Switzerland incidences of osteoporotic hip,
vertebral and distal forearm fracture will rise by 33%,
27%, and 19%, respectively, between 2000 and 2020, if
current prevention and treatment patterns are main-
tained. Corresponding absolute fracture numbers will
rise by 36%, 31%, and 23%. Related direct medical
inpatient costs are predicted to increase by 33%; how-
ever, this estimate is subject to uncertainty due to limited
availability of input data.
Keywords Economics Æ Epidemiology Æ Europe Æ
Modeling studies Æ Osteoporosis Æ Switzerland
Introduction
Osteoporosis is an important health problem in elderly
women and, to a lesser extent, in elderly men [1]. Oste-
oporotic fragility fractures occur at multiple sites of the
skeletal system [2], but the main focus of research is on
fractures of the hip, vertebrae and distal forearm [1].
These fracture types occur frequently and show a steep
rise in incidence with age, more pronounced in women
than in men [1, 3]. Most serious consequences are ob-
served in hip and vertebral fracture patients. The impact
of hip fracture is dramatic in terms of morbidity, mor-
tality, loss of functional independence, and cost [1, 4].
Worldwide projections have predicted a doubling of
hip fracture cases from 1990 to 2025, with the ageing of
the populations being one of the most important causes
[5, 6]. The expected rise will be particularly pronounced
in Asia, but Western societies will be affected, too [5, 7].
Despite an awareness of these general trends,
detailed simulations of the future impact of osteoporosis
are rare. Several Markov-based modeling studies have
assessed lifetime fracture risk and long-term fracture
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consequences [8, 9, 10, 11], but only one, focusing on the
situation in Florida, has examined the expected health
burden of osteoporosis in the first quarter of the 21st
century [12].
In Switzerland, countrywide data on the occurrence
and impact of osteoporotic fractures are sparse, with the
last comprehensive assessment describing the situation
in 1992 [13]. Forecasts of future fracture incidences and
impact were based on these data and did not apply up-
to-date modeling techniques [14, 15]. A Swiss Markov
model, addressing the socioeconomic impact of hip
fracture, has been published as a short report only [16].
A clear lack of planning data has been recognized by the
health authorities.
Given this situation, we aimed at developing a Mar-
kov-based modeling framework using Monte Carlo
simulation, suitable to quantify the incidence, absolute
number and economic impact of osteoporotic hip, ver-
tebral and distal forearm fractures, currently and in the
future. Intended features were applicability to a wide
variety of countries and situations, and the ability to
assess the impact of future changes in disease incidence,
osteoporosis-related medical practice, and cost. The first
application was to the Swiss population in 2000, 2010
and 2020. The methodological objective of this appli-
cation was to test the model in a well-defined and stable
Western population with a high share of elderly people.
At the same time the existing knowledge gap with re-
spect to the current situation and the developments to be
expected in Switzerland was to be filled.
Materials and methods
Model characteristics
Using DATA Professional (Tree Age, Williamstown,
Mass., USA), we developed a four-stage Markov pro-
cess model comprising the following mutually exclusive
health states: alive without fracture; alive with at least
one distal forearm or vertebral fracture, but no hip
fracture; alive with at least one hip fracture; dead. Other
fracture sites were not taken into account. We used
Monte Carlo simulation to run a large number of indi-
viduals through the model separately, allowing for a
subject-by-subject random assignment of characteristics.
We used tracker variables to record individual event
histories, taking into account non-osteoporotic and
osteoporotic fractures, acute hospital care, inpatient
rehabilitation episodes, nursing home admissions, and
cost. Thus, the ‘‘memory-less’’ feature of Markov cohort
models was overcome [17].
We modeled all event entries using a cycle length of 1
month, in order to reduce any distortions related to the
time distribution of events occurring. An individual
could sustain one fracture per cycle. Rates were con-
verted into cumulative probabilities to allow for correct
Markov state transitions between cycles [18]. Where
appropriate, a half-cycle correction was implemented.
For the application to Switzerland, two different
kinds of simulation were used. First, a cohort repre-
senting the Swiss population of a certain year aged 50
years or older was observed for 1 year. Based on a
random assignment of gender and age, 500,000 simu-
lated persons were run through the model. Total and
osteoporosis-related hip, vertebral, and distal forearm
fractures were counted. We observed fracture-related
resource use and costs for another 6 months, without
allowing for additional fracture entries, in order to
achieve a mean follow-up time of 1 year after fracture
entry. Second, a cohort representing all Swiss persons
aged 50 years in a certain year was observed for the
remainder of their lives. Based on a random assignment
of gender, 12,500 simulated persons were run through
the model. Costs were calculated undiscounted and
discounted by 3% per year. Inflation or changes in
inpatient care cost due to changing medical practice
were not modeled. Owing to the extended observation
period per subject, the relative importance of long-term
nursing home costs was adequately taken into account.
On this basis, estimates of mean yearly inpatient costs
due to recent, as well as earlier, fractures could be cal-
culated.
Model inputs
Published or publicly available Swiss data sources were
used wherever possible. Otherwise, European data and,
if necessary, data from the USA and Australia were
used. Plausibility of all model inputs was assessed by
comparison with published literature.
Demographic data: The Swiss Federal Statistical Of-
fice (SFSO) has issued a series of demographic scenarios
projecting the development of the Swiss population be-
tween 2000 and 2060 [19]. Age and gender distributions
used in the main analysis are those described by the
SFSO main scenario, which extrapolates current demo-
graphic trends and thus avoids extreme assumptions. In
this scenario, the proportion of the population aged 50
years or over will rise from 33.3% in 2000 to 41.3% in
2020. The share of those aged 65 or over will rise from
15.4% to 20.0%. Figure 1 compares the age distribu-
tions expected for 2000 and 2020.
Fracture incidences: Swiss hospitals are obliged to
report patient-level inpatient data to the SFSO. Gender-
and age-specific hip fracture incidences were estimated
from the ICD-10 S72.0–S72.2 cases reported to the
SFSO in 2000, with the assumption of a hip fracture
hospitalization rate of 100%. Reporting was incomplete,
and the SFSO calculated a relation of reported to ex-
pected cases of 0.811. This figure was used with the
assumption of a random distribution of non-reporting.
Swiss-based gender- and age-specific data on vertebral
and distal forearm fracture incidence were not available.
Cases reported to the SFSO could not be used here, as
valid Swiss data on hospitalization probabilities do not
exist. Published data show that hip fracture rates are
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similar in Switzerland and in Western Europe [6, 20]. It
was assumed that the same relationship exists for other
types of osteoporotic fractures, and morphometric ver-
tebral fracture incidences for Western Europe reported
by the EPOS group were used [21]. Missing data points
after age 79 years were estimated by linear extrapolation
[21, 22, 23, 24]. In the case of distal forearm fracture, the
incidences reported by Kanis et al. for Malmo¨, Sweden,
provided sufficient detail [23]. These were multiplied by a
correction factor of 0.55, derived from the EVOS data,
as distal forearm fracture incidences are higher in
Northern Europe than in Western Europe [1, 25]. Inci-
dences above age 89 years were assumed to be identical
to those in the age group 85–89 years [22, 23, 24]. The
incidence rates used are summarized in Table 1.
Osteoporosis-attributable fractures: The share of
osteoporosis-attributable fractures, i.e., of fractures that
would not have occurred if no osteoporotic changes had
been present in the skeletal system, by fracture type,
gender and age was modeled by way of a stochastic
process that used the attribution probabilities described
by Melton et al. for the white population in the USA
[26]. Calculation of osteoporosis-attributable fracture
incidences and numbers at the total population level
assumed no osteoporosis-related fractures under the age
of 50 years.
Mortality: All-causemortality by year, gender and age
was taken from the SFSO main demographic scenario
[19]. Short- and long-term excess mortality after hip
fracture was modeled from data collected by Trombetti
Fig. 1 Age distribution of the
Swiss population, 2000 and
2020 compared, according to
the Swiss Federal Statistical
Office’s main demographic
scenario
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et al. in canton Geneva, Switzerland [27]. Those authors
observed an unadjusted in-hospital mortality rate of 8%
in women and 15% in men. The combination of their
original data and the Swiss age distribution starting at age
50 years led to an age-adjusted excess mortality rate of 53
per 1,000 person-years in women and 206 per 1,000 per-
son-years in men, in the first year after fracture. In the
second to fifth years, excess mortality rates per year were
103 per 1,000 person-years in women and 127 per 1,000
person-years in men. Long-term excess mortality after
vertebral fracture was modeled on relative risks of 1.6 in
women and 1.2 in men, as found in the EPOS study after
multivariate adjustment [28, 29, 30]. For both types of
fracture, excessmortalitywas limited to a periodof 5 years
after fracture entry [10, 27, 29, 31, 32]. Excess mortality
after distal forearm fracture and short-term excess mor-
tality after vertebral fracture were not modeled [1]. To
avoid an overestimation of total mortality, all-cause
mortality was reduced by the approximate population-
level impact of fracture-associated mortality.
The probability that a vertebral fracture would come
to clinical attention and be treated was estimated to be
30% [33, 34, 35]. The probability of an acute hospital-
ization episode was assumed to be 33% after a vertebral
fracture had come to clinical attention [1, 35]. In the case
of distal forearm fracture, a hospitalization probability
of 53.0% was estimated from the incidence data used
and the inpatient cases with ICD-10 codes S52.5–6 re-
ported to the SFSO in 2000. This estimate takes into
account all patients that occupy a hospital bed, even be
it for a few hours only.
Year 2000 acute care lengths of stay were calculated
from the SFSO data. In the case of vertebral fracture,
ICD-10 codes M48.5, M80.0–9, M84.0, M84.4 and T08
were taken into account. Participation in an inpatient
rehabilitation program after hip fracture was assumed to
occur in 68% of women and 36% of men, with a length
of stay of 59 and 54 days, respectively [27]. Rehabilita-
tion programs after vertebral or distal forearm fracture
were not taken into account.
Swiss year 2000 census data were used to estimate
gender- and age-specific probabilities of being cared for
in a nursing home, and of being admitted to such an
institution, for any reason. The overall share of fracture-
induced nursing home admissions was assumed to be
8%, following a German source [36]. Based on data
from canton Geneva, Switzerland, the overall proba-
bility of long-term nursing home admission after hip
fracture in those living in an apartment before the
fracture event was assumed to be 18% [27, 37]. Gender-
and age-specific admission probabilities were estimated
under the assumption of a linear increase with age.
Residency in a nursing home for any reason and the
event of being admitted to a nursing home due to hip
fracture were modeled in parallel. Residency in a nursing
home was counted as fracture-induced until a nursing
home admission for any reason would have occurred.
Nursing home admissions due to vertebral or distal
forearm fractures were not taken into account.
Adopting a societal perspective, we assessed direct
medical costs of acute inpatient hospital care, inpatient
rehabilitation and nursing home residency by multiply-
ing length of stay with the estimated daily real costs by
type of institution as reported by the SFSO for the year
2000. The results were verified against Swiss and inter-
national data sources [38, 39, 40, 41]. All costs are
indicated in year 2000 Swiss francs (CHF). On 31 Dec
2000, CHF1 equaled 0.66 euros.
Analysis of model output
Using STATA/SE (version 8.0, Stata Corporation,
College Station, Tex., USA) and standard statistical
procedures, we analyzed the output data. Calculation of
95% confidence intervals (95% CIs) was based on bias-
corrected bootstrapping using 1,000 repetitions. Due to
limitations of available computation time, calculation of
CIs was restricted to key output parameters.
Internal and external model validation
Correct reproduction of main input parameters was
examined to test the internal validity of the model.
Comparisons included the gender and age distributions
and life expectancies of the underlying demographic
scenario, as well as gender- and age-specific incidence
rates. External plausibility of results was assessed by
comparison with published data as detailed in the Dis-
cussion.
Sensitivity analysis
While Monte Carlo simulation was used to deal with
first-order uncertainty (individual variation in gender
and age), the impact of second-order parameter uncer-
tainty was assessed by classic deterministic sensitivity
Table 1 Gender- and age-specific fracture incidence rates, per 1,000
person-years, as used in the main analysis
Age (years) Hip fracture Vertebral
fracturea
Distal forearm
fracture
Female Male Female Male Female Male
50–54 0.31 0.49 3.6 0.9 2.3 0.6
55–59 0.68 0.79 5.5 5.5 2.5 0.8
60–64 1.09 0.91 9.5 4.8 3.1 0.8
65–69 2.15 1.59 12.3 6.3 3.8 1.6
70–74 4.14 2.29 17.9 8.7 5.0 0.5
75–79 8.51 4.49 29.3 13.6 5.7 1.0
80–84 17.71 7.46 34.4b 16.1b 6.7 1.4
85–89 32.31 14.84 39.6b 18.7b 7.7 1.8
90–94 41.43 24.96 44.7b 21.2b 7.7c 1.8c
95+ 44.04 46.28 49.9b 23.8b 7.7c 1.8c
aRadiographic fractures
bExtrapolated from the available datapoints
cAssumed to remain constant after age 85–89 years
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analysis. Ranges of variation are shown in Table 2. In
order to limit calculation time, we combined several
parameter changes that prompted fewer fracture events
and lower costs, and tested them simultaneously in a
best-case scenario. Parameter changes that prompted
more fracture events and higher costs were tested in a
worst-case scenario. Varied parameters comprised: gen-
der- and age-specific incidences; osteoporosis attribution
probabilities; treatment, hospitalization and rehabilita-
tion probabilities; the probability of a new admission to
a nursing home after hip fracture; lengths of stay; acute
care, rehabilitation and nursing home costs per day. In a
separate analysis, approximate outpatient hip fracture
costs of CHF6,442 per case were added [42]. Back-
ground nursing home residency and disease-specific
mortality were also varied separately. Additional anal-
yses modeled disease-specific mortality as age-specific or
replaced the SFSO main demographic scenario with
alternative scenarios that described either a less or a
more pronounced ageing of the population [19]. Finally,
we repeated the main analysis but included a secular 1%
per year rise of gender- and age-specific hip fracture
incidence rates [1, 6].
Results
Internal validation
The gender and age distributions of the underlying
demographic scenario were reproduced correctly. The
proportion of women in the population aged 50 years or
older was 54.6% (95% CI 54.4–54.7) in 2000, 53.8%
(95% CI 53.7–53.9) in 2010 and 53.5% (95% CI 53.3–
53.6) in 2020. Mean age ± SD of those aged 50 years or
older rose from 65.0±11.0 (95% CI 64.9–65.0) years in
2000 and 65.2±10.9 (95% CI 65.2–65.2) years in 2010 to
65.6±10.8 (95% CI 65.6–65.6) years in 2020. Predicted
life expectancy at age 50 years was 31.8±10.4 (95% CI
31.7–32.0) years in 2000, 32.8±10.1 (95% CI 32.6–32.9)
years in 2010 and 33.4±9.6 (95% CI 33.3–33.6) years in
2020. These results compare well with the SFSO esti-
mates of 32.0 years in 2000, 32.8 years in 2010 and 33.4
years in 2020. Gender- and age-specific fracture inci-
dences used on the input side were also reproduced
correctly. First hip fractures were estimated to occur at
an age of 79.8 years, on average, in 2000. This compares
well with a broad estimate of 80.5 years as directly de-
rived from the SFSO data. In the latter case, no dis-
tinction between first and repeated fractures could be
made.
Fractures
Tables 3 and 4 summarize total and osteoporosis-
attributable fracture incidences and absolute fracture
numbers by gender. For all parameters a rise is seen
between 2000 and 2020, with the exception of the inci- T
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Table 3 Female population: fracture incidences per 1,000 person-years (95% CIs) and total fracture numbers in Switzerland
Parameter Hip fracture Vertebral fracturea Distal forearm fracture
Year 2000 2010 2020 2000 2010 2020 2000 2010 2020
Female population from age 50 years
Incidence 5.56 5.59 5.88 15.10 15.27 15.43 4.00 3.91 4.00
(5.28–5.85) (5.29–5.87) (5.58–6.17) (14.64–15.56) (14.82–15.76) (14.98–15.93) (3.76–4.25) (3.68–4.16) (3.75–4.23)
Incidence attributable to osteoporosis 5.07 5.15 5.34 13.52 13.65 13.86 2.92 2.80 2.85
(4.80–5.33) (4.87–5.43) (5.06–5.59) (13.08–13.95) (13.21–14.09) (13.40–14.31) (2.72–3.13) (2.60–2.99) (2.66–3.06)
Total fracture number 7,266 8,171 9,589 19,722 22,317 25,169 5,228 5,718 6,522
Total female population
Incidence attributable to osteoporosisb 1.80 2.00 2.30 4.80 5.32 5.98 1.04 1.09 1.23
Total fracture number attributable to osteoporosisb 6,618 7,518 8,702 17,665 19,947 22,595 3,815 4,088 4,650
aRadiographic fractures. For estimates on clinical fractures, divide values by 3
bAssuming no osteoporosis-related fractures in the population under age 50 years
Table 4 Male population: fracture incidences per 1,000 person-years (95% CIs) and total fracture numbers in Switzerland
Parameter Hip fracture Vertebral fracturea Distal forearm fracture
Year 2000 2010 2020 2000 2010 2020 2000 2010 2020
Male population from age 50 years
Incidence 2.07 2.20 2.31 6.44 6.57 6.92 0.86 0.88 0.92
(1.89–2.25) (2.02–2.38) (2.13–2.52) (6.12–6.78) (6.24–6.90) (6.61–7.26) (0.75–0.98) (0.77–1.01) (0.81–1.06)
Incidence attributable to osteoporosis 1.61 1.71 1.86 5.43 5.44 5.82 0.36 0.36 0.37
(1.45–1.77) (1.55–1.87) (1.70–2.04) (5.13–5.75) (5.13–5.75) (5.51–6.13) (0.29–0.45) (0.30–0.45) (0.30–0.46)
Total fracture number 2,249 2,764 3,274 7,004 8,248 9,821 931 1,110 1,309
Total male population
Incidence attributable to osteoporosisb 0.50 0.60 0.73 1.68 1.90 2.29 0.11 0.13 0.15
Total fracture number attributable to osteoporosisb 1,755 2,149 2,644 5,913 6,820 8,270 393 456 531
aRadiographic fractures. For estimates on clinical fractures, divide values by 3
bAssuming no osteoporosis-related fractures in the population under age 50 years
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dence of distal forearm fractures in women aged 50
years and over, which is constant at the all-fracture level
and slightly decreases when only osteoporosis-attribut-
able fractures are taken into account. Related absolute
minima will occur in 2010.
For all ages combined, osteoporosis-attributable hip
fracture incidence will rise from 1.16 to 1.54 per 1,000
person-years (+32.8%), osteoporosis-attributable ver-
tebral fracture incidence from 3.28 to 4.18 per 1,000
person-years (+27.4%), and osteoporosis-attributable
distal forearm fracture incidence from 0.59 to 0.70 per
1,000 person-years (+18.6%). Osteoporosis-attribut-
able fracture numbers at the total population level will
rise from 8,375 to 11,353 (+35.6%) in the case of hip
fracture, from 23,584 to 30,883 (+30.9%) in the case of
vertebral fracture, and from 4,209 to 5,186 (+23.2%) in
the case of distal forearm fracture.
Lifetime fracture risk
For all combinations of fracture type and gender, life-
time risk at age 50 years will rise between 2000 and 2020.
Lifetime hip fracture risk will rise from 14.7% to 16.4%
(women: 20.9% to 23.1%, men: 8.7% to 9.7%). Lifetime
vertebral fracture risk will rise from 30.7% to 33.8%
(women: 42.6% to 46.1%, men: 19.1% to 21.7%), and
distal forearm fracture risk from 8.1% to 8.9% (women:
13.8% to 14.9%, men: 2.7% to 3.1%). Osteoporosis-
attributable lifetime risk will rise from 13.0% to 14.4%
(women: 19.2% to 21.2%, men: 7.0% to 7.6%) in the
case of hip fracture, from 27.8% to 30.7% (women:
39.0% to 42.5%, men: 17.0% to 19.0%) in the case of
vertebral fracture, and from 5.6% to 6.1% (women:
10.1% to 10.9%, men: 1.2% to 1.5%) in the case of
distal forearm fracture.
Resource use
Table 5 shows the number of acute hospitalizations and
the days spent in acute care hospitals, inpatient reha-
bilitation facilities, and nursing homes, due to fractures,
in 1000 persons aged 50 years and over, in 2000, 2010
and 2020. Results for the Swiss population from age 50
on are added. Days of stay occurring until 1 year after
fracture entry are taken into account. For all parame-
ters, a rise is seen between 2000 and 2020. However,
estimates per 1,000 persons show a non-monotonic
development in some cases, with their maxima or min-
ima in 2010. Population-level increases are more pro-
nounced due to the growth of population size.
Costs
Figure 2 shows direct medical inpatient costs arising in
the Swiss population from age 50 on, induced by frac-
tures in 2000, 2010 and 2020, during the first year after T
a
b
le
5
N
u
m
b
er
s
o
f
d
a
y
s
sp
en
t
in
d
iff
er
en
t
ty
p
es
o
f
in
st
it
u
ti
o
n
s,
u
n
ti
l
1
y
ea
r
a
ft
er
fr
a
ct
u
re
en
tr
y
,
d
u
e
to
h
ip
,
v
er
te
b
ra
l
a
n
d
d
is
ta
l
fo
re
a
rm
fr
a
ct
u
re
s
o
cc
u
rr
in
g
in
th
e
y
ea
r
o
f
re
fe
re
n
ce
P
a
ra
m
et
er
A
ll
fr
a
ct
u
re
s
O
st
eo
p
o
ro
si
s-
re
la
te
d
fr
a
ct
u
re
s
Y
ea
r
2
0
0
0
2
0
1
0
2
0
2
0
In
cr
ea
se
2
0
0
0
2
0
1
0
2
0
2
0
In
cr
ea
se
2
0
0
0
–
2
0
2
0
2
0
0
0
–
2
0
2
0
P
er
1
,0
0
0
p
er
so
n
s
fr
o
m
a
g
e
5
0
y
ea
rs
a
N
u
m
b
er
o
f
a
cu
te
h
o
sp
it
a
li
za
ti
o
n
s
6
.4
0
6
.4
7
6
.5
5
+
2
.3
%
5
.3
3
5
.4
1
5
.5
0
+
3
.2
%
(6
.1
8
–
6
.6
2
)
(6
.2
5
–
6
.6
9
)
(6
.3
3
–
6
.7
8
)
(5
.1
3
–
5
.5
4
)
(5
.2
1
–
5
.6
2
)
(5
.3
0
–
5
.7
1
)
D
a
y
s
in
a
cu
te
ca
re
h
o
sp
it
a
ls
9
5
.6
9
7
.5
9
9
.2
+
3
.4
%
8
2
.7
8
4
.5
8
6
.3
+
4
.4
%
(9
2
.6
–
9
9
.3
)
(9
4
.1
–
1
0
1
.0
)
(9
5
.8
–
1
0
2
.6
)
(7
9
.6
–
8
6
.3
)
(8
1
.6
–
8
8
.1
)
(8
3
.0
–
8
9
.5
)
D
a
y
s
in
in
p
a
ti
en
t
re
h
a
b
il
it
a
ti
o
n
fa
ci
li
ti
es
1
3
9
.0
1
4
2
.5
1
4
1
.7
+
1
.9
%
1
2
3
.2
1
2
8
.2
1
2
7
.7
+
3
.7
%
(1
3
1
.3
–
1
4
7
.5
)
(1
3
4
.6
–
1
5
0
.1
)
(1
3
3
.6
–
1
4
9
.4
)
(1
1
6
.1
–
1
3
1
.0
)
(1
2
0
.6
–
1
3
5
.2
)
(1
2
0
.4
–
1
3
5
.2
)
D
a
y
s
in
n
u
rs
in
g
h
o
m
es
1
4
9
.9
1
4
6
.5
1
5
6
.5
1
3
2
.8
1
3
3
.2
1
4
4
.3
(1
2
9
.4
–
1
7
0
.3
)
(1
2
8
.5
–
1
6
5
.0
)
(1
3
6
.7
–
1
7
8
.2
)
+
4
.4
%
(1
1
3
.9
–
1
5
1
.9
)
(1
1
6
.2
–
1
5
2
.4
)
(1
2
5
.4
–
1
6
6
.0
)
+
8
.7
%
S
w
is
s
p
o
p
u
la
ti
o
n
fr
o
m
a
g
e
5
0
y
ea
rs
N
u
m
b
er
o
f
a
cu
te
h
o
sp
it
a
li
za
ti
o
n
s
1
5
,3
2
0
1
7
,5
5
9
1
9
,9
7
7
+
3
0
.4
%
1
2
,7
6
3
1
4
,6
9
7
1
6
,7
8
0
+
3
1
.5
%
D
a
y
s
in
a
cu
te
ca
re
h
o
sp
it
a
ls
2
2
9
,0
1
3
2
6
4
,8
4
2
3
0
2
,5
4
5
+
3
2
.1
%
1
9
7
,9
8
7
2
3
0
,1
3
0
2
6
3
,3
1
4
+
3
3
.0
%
D
a
y
s
in
in
p
a
ti
en
t
re
h
a
b
il
it
a
ti
o
n
fa
ci
li
ti
es
3
3
2
,8
4
2
3
8
7
,0
5
9
4
3
2
,1
8
5
+
2
9
.8
%
2
9
5
,0
6
6
3
4
8
,1
4
4
3
8
9
,6
3
1
+
3
2
.0
%
D
a
y
s
in
n
u
rs
in
g
h
o
m
es
3
5
8
,8
9
0
3
9
5
,4
1
4
4
7
7
,4
0
3
+
3
3
.0
%
3
1
7
,8
8
0
3
6
1
,8
3
3
4
4
0
,0
9
4
+
3
8
.4
%
a
N
u
m
b
er
s
in
p
a
re
n
th
es
es
a
re
9
5
%
co
n
fi
d
en
ce
in
te
rv
a
ls
665
fracture. Costs of all fractures and of those attributable
to osteoporosis are presented in parallel.
Total first-year inpatient costs will rise by 31.5% at
the all-fracture level, from CHF443.7 million (CI 422.8–
462.9 million) to CHF583.5 million (CI 559.2–
609.7 million). Point estimates correspond to 1.0% and
1.3% of Swiss health care expenditure in 2000. At the
osteoporosis-attributable fracture level there will be a
rise by 33.5%, from CHF388.2 million (CI 369.1–
406.4 million) to CHF518.3 million (CI 494.9–
544.7 million). Point estimates correspond to 0.9% and
1.2% of Swiss health care expenditure in 2000.
The relative shares of acute care hospital, inpatient
rehabilitation and nursing home costs in the first year
after osteoporosis-related fracture will remain fairly
constant over time. In 2000, acute hospital care con-
tributes 51.5% (2020: 51.3%), inpatient rehabilitation
contributes 33.4% (2020: 33.1%), and nursing home
care 15.1% (2020: 15.7%). Results at the all-fracture
level are similar.
The relative importance of nursing home costs is
much higher if undiscounted lifetime inpatient costs
from age 50 years on are considered. Long-term cost
consequences of fractures are included in this perspec-
tive, which results in a proportion of nursing home costs
that is near constant over time at 53.3%–54.3%.
These percentages broadly reflect the contribution of
nursing home costs to yearly fracture- and osteoporotic
fracture-induced inpatient costs taking into account the
consequences of earlier fractures. If an average value of
53.8% is adopted, yearly fracture-related inpatient costs
can be estimated at CHF817.2 million in 2000 and at
CHF1,072.4 million in 2020 (+31.2%), which corre-
spond to 1.9% and 2.5% of Swiss health care expendi-
ture in 2000. Osteoporosis-attributable costs can be
estimated at CHF713.4 million in 2000 and at
CHF946.2 million in 2020 (+32.6%), which correspond
to 1.6% and 2.2% of Swiss health care expenditure in
2000.
Lifetime fracture-related inpatient costs from age 50
on, per 1,000 persons observed, will rise from
CHF13.7 million in 2000 (CI 12.3–15.4 million; dis-
counted by 3%: CHF5.4 million) to CHF15.2 million in
2020 (CI 13.8–16.6 million; discounted: CHF5.7 mil-
lion). If only osteoporosis-attributable fractures are re-
garded, the rise will be from CHF11.9 million in 2000
(CI 10.6–13.3 million; discounted: CHF4.6 million) to
CHF13.5 million in 2020 (CI 12.3–15.0 million; dis-
counted: CHF5.0 million).
Sensitivity analysis
The effects of input parameter variation on key outcome
parameters are shown in Table 6.
Implementation of the best and worst case scenarios
described in the Methods strongly impacted on all epi-
demiologic and economic outcome parameters. For
example, the incidence of year 2000 osteoporosis-
attributable hip fractures, for all ages combined, was
changed by ±31.9%. Population level, osteoporosis-
attributable, first-year inpatient costs were reduced by
57.7% in the best case and increased by 93.7% in the
worst case. If estimated outpatient hip fracture costs of
CHF6,552 per case were taken into account, this led to
an absolute increase of osteoporosis-attributable costs
Fig. 2 Inpatient costs of fractures of the hip, vertebrae and
forearm, until 1 year after fracture entry, occurring in the Swiss
population from age 50 years
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Table 6 Effects of input parameter variation on key outcome parameters (see Materials and methods section and Table 2 for details and ranges of input parameter variation)
Parameter Year Main
analysis
Best
case
scenarioa
Worst
case
scenarioa
Inclusion of
out-patient
hip
fracture costs
Disease-specific
mortality
Proportion of popu-
lation living in nurs-
ing homes
Less-pronounced
ageingb
More-pronounced
ageingb
Secular
rise in hip
fracture
incidence
Lower Higher Lower Higher
Population from
age 50 years
Incidence of hip
fracture per 1,000
person-years
2000 3.97 3.20 4.83 No effect 3.97 4.05 No effect No effect 3.97 3.97 3.97
2020 4.23 3.41 5.02 No effect 4.20 4.22 No effect No effect 4.13 4.29 5.07
Percent change +6.5 +6.6 +3.9 – +5.8 +4.2 – – +4.0 +8.1 +27.7
Days in acute care
hospitals due to
osteoporotic
fractures per
1,000 persons
2000 82.7 35.4 162.9 No effect 81.0 83.2 No effect No effect 82.7 82.7 82.7
2020 86.3 38.6 166.2 No effect 86.4 87.7 No effect No effect 86.9 87.5 101.1
Percent change +4.4 +9.0 +2.0 – +6.7 +5.4 – – +5.1 +5.8 +22.2
Total population
Incidence of
osteoporotic hip
fracture per 1,000
person-years
2000 1.16 0.79 1.53 No effect 1.16 1.19 No effect No effect 1.16 1.16 1.16
2020 1.54 1.05 1.97 No effect 1.53 1.54 No effect No effect 1.47 1.64 1.87
Percent change +32.8 +32.9 +28.2 – +31.2 +29.4 – – +26.7 +41.2 +61.2
Number of
osteoporotic
hip fractures
2000 8,375 5,710 11,001 No effect 8,322 8,560 No effect No effect 8,375 8,375 8,375
2020 11,353 7,782 14,542 No effect 11,305 11,347 No effect No effect 11,252 11,682 13,783
Percent change +35.6 +36.3 +32.2 – +35.8 +32.6 – – +34.4 +39.5 +64.6
First-year inpatient
costs due to
osteoporotic
fractures
(million CHF)
2000 388.2 164.4 751.9 441.6 380.1 388.2 392.9 385.2 388.2 388.2 388.2
2020 518.3 228.7 965.2 590.6 518.1 512.8 523.9 513.2 525.5 523.2 611.4
Percent change +33.5 +39.1 +28.4 +33.7 +36.3 +32.1 +33.3 +33.2 +35.4 +34.8 +57.5
aCombined variation of gender- and age-specific incidences; osteoporosis attribution probabilities; treatment, hospitalization and rehabilitation probabilities; probability of new
admission to nursing home after hip fracture; lengths of stay; acute care, rehabilitation and nursing home costs per day
bAlternative SFSO demographic scenarios, ‘‘less pronounced ageing of the population’’ and ‘‘more pronounced ageing of the population’’
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by 13.8%. In contrast, if we varied the proportion of the
population that were living in a nursing home, varied the
level of disease-specific mortality, or modeled disease-
specific mortality as age-specific, it hardly affected the
absolute results. Relative parameter changes between
2000 and 2020 were only marginally affected by all
modifications named so far. When the SFSO main
demographic scenario was replaced by alternative sce-
narios that described a less-pronounced or a more-pro-
nounced ageing of the population, relative increases in
the incidence of osteoporosis-attributable fractures be-
tween 2000 and 2020 were slightly less pronounced in the
former case and more pronounced in the latter (in the
case of hip fracture, +26.7% and +41.2% compared to
+32.8% in the main analysis). However, there was no
impact on the resource use and cost results. When a 1%
per year secular rise in the incidences of gender- and age-
specific hip fractures was modeled, relative changes be-
tween 2000 and 2020 were inflated by a factor of 2 to 4
when compared with the main analysis. The incidence of
osteoporosis-attributable hip fractures increased by
+61.2%, and population level, osteoporosis-attribut-
able, first-year inpatient costs by +57.5%.
Discussion
The modeling framework described here allows one to
assess the epidemiologic and economic consequences of
osteoporotic hip, vertebral and distal forearm fractures.
There is a particular focus on change over time, e.g.,
related to demographic developments. If suitable input
data are available, the model can be applied to a wide
variety of countries and settings. While the application
to Switzerland, presented here as a test case, was purely
descriptive, the epidemiological and economic impact of
new preventive or treatment strategies, or of any chan-
ges occurring in medical practice, can easily be modeled
as soon as related effect estimates are available.
To our knowledge this is the second study, interna-
tionally, that used a Markov process model, and the first
one that used the Monte Carlo technique, to simulate
the development of osteoporotic fracture incidences and
numbers, associated resource use, and cost over an ex-
tended period of time [12]. While future fracture occur-
rence alone could be estimated by simpler means, the
synthesis of data from various sources and the assess-
ment of several interlinked output parameters are most
consistently achieved by the use off the Markov ap-
proach. More importantly, long-term observation of
simulated individual disease histories, e.g., allowing for
the estimation of lifetime fracture risk, requires such a
methodology [12, 17]. The advantages of Monte Carlo
simulation in particular are highlighted by a comparison
with the methodological approach described in a re-
cently published work by Burge et al., who assessed the
epidemiology and economic impact of osteoporosis in
Florida for 2000–2025 [12]. Relying on a conventional
Markov cohort model, Burge et al. had to run a large
number of separate simulations, one for each combina-
tion of year of age and race. Simulation outputs were
combined, and the impact of demographic change was
assessed by way of separate procedures outside the
Markov module. By contrast, the Monte Carlo tech-
nique enabled us to forego additional modeling steps.
Additional calculations were limited to the statistics re-
quired to address the chance component inherent in all
Monte Carlo-based results.
While models are generally characterized by a
reduction in complexity compared to reality, some sim-
plifications in the present case were dictated by an
anticipated lack of appropriate input data. For example,
we relied on a set of Markov states that solely described
fracture event history, in contrast to some osteoporosis
models that incorporated functional status or type of
residence at the disease state level [8, 10, 16]. Owing to a
lack of detailed fracture incidence data that distin-
guished between persons without and with osteoporosis,
modeling of fracture entries was not based on the ab-
sence or presence of the underlying disease [10]. Differ-
ent fracture incidences in persons without or with
previous fractures, or in persons living either in the
community or in nursing homes, were not taken into
account [10]. The model was built in such a way that the
simplifications described can be abandoned easily when
adequate input data become available. Technical cor-
rectness of the model was assessed by comparison of
output parameters with related input parameters, with
completely satisfactory results.
Besides developing and testing methodology, this
study aimed at closing a gap of information on the fu-
ture occurrence and consequences of osteoporosis-
attributable hip, vertebral, and distal forearm fractures
in Switzerland. According to our results, the incidence of
these fracture types at the Swiss population level will rise
by 19%–33% between 2000 and 2020. Corresponding
absolute fracture numbers will rise by 23%–36%. Re-
lated direct medical inpatient costs per year are pre-
dicted to increase by 33%.
The expected increase in the number of osteoporosis-
related hip fractures, from 8,375 in 2000 to 11,353 in
2020, confirms the magnitude of earlier estimates [1, 6,
7]. For Switzerland in 2020, Meine et al. [15] expected
15,000 hip fractures and Lippuner and Jaeger [14] ex-
pected 14,436, for all ages combined and without
excluding non-osteoporotic fractures. Calculated life-
time risks are well in the range to be expected from the
literature. For example, our result of a 21% lifetime hip
fracture risk in women aged 50 years in 2000 compares
well with published estimates from various industrialized
countries, indicating a risk of 14%–23% at this age [4, 8,
10, 20, 23]. In men aged 50 years, our result of 9%
compares with published estimates of from 6%–11%
[23, 35, 43].
Constant or slightly decreasing incidence rates of
distal forearm fractures, as observed in women aged 50
years and over, and non-monotonic developments over
time in some resource use parameters, are explained by
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shifts in the age structure above age 50 as modeled by
the SFSO main scenario. Residual influences of chance
may have played an additional role.
For the fracture types taken into account here,
Lippuner et al. reported 290,972 osteoporosis-
attributable days spent in acute care hospitals in 1992
and related costs of CHF245.9 million [13]. Our cor-
responding results of 197,987 hospital days and costs of
CHF199.8 million in 2000 are distinctly lower. While
the different registration methods and coding systems
used might have contributed to this effect, the main
reason lies in reduced lengths of stay. In particular,
mean acute care length of stay after hip fracture fell
dramatically, from 29.1 days in 1992 to 17.7 days in
2000 [13]. It can be assumed that this decrease was
enabled by improved medical practice but also
encouraged by budgetary constraints in the Swiss
health care system. It may have been accompanied by a
still unmeasured increase in the use of outpatient
medical and nursing services and, consequently, in
outpatient costs. Missing information on outpatient
costs hindered a realistic assessment of total direct
medical costs.
The finding that long-term nursing home costs con-
tributed 54% of total inpatient costs is consistent with
findings from 1998 onwards, which indicated that long-
term care costs are responsible for 40%–75% of osteo-
porosis-related inpatient costs in the USA [12].
Sensitivity analyses demonstrated stable relative
parameter changes between 2000 and 2020 except for
when a 1% per year secular rise of fracture incidence
was modeled. In fact, there is no strong evidence for an
ongoing secular rise in Europe or in the USA [1, 6].
Absolute results, however, showed considerable varia-
tion, which highlighted that relevant uncertainty was
present in some of the input parameters available. These
were of different quality and, in part, of non-Swiss ori-
gin. For example, for vertebral and distal forearm
fractures, European incidence data had to be used and,
in the latter case, adjusted for geographic differences.
This was justified by various literature sources, but, still,
the inputs derived may, to a certain extent, deviate from
Swiss reality [22, 25, 35, 44].
The osteoporosis attribution probabilities applied,
reported by Melton et al., were estimated by an expert
panel that used a Delphi process, and they compare well
with earlier estimates published by Phillips et al. [26, 45].
Attribution probabilities have been used by several au-
thors to model osteoporosis-related fracture occurrence
[12, 13].
Modeling of hip fracture mortality was based on
Swiss short-term and long-term data reported by
Trombetti et al. [27], which are in line with various Swiss
and international data sources [31, 37, 46]. In particular,
1-year cumulative mortality was near identical in the
study by Trombetti et al. (women: 19%, men: 39%), in
an earlier Swiss study by Schu¨rch et al. (women: 21%,
men: 35%) [37], and in the Australian study by Center
et al. (women: 20%; men: 37%) [31].
The estimate of a 53% hospitalization probability
after distal forearm fracture in the population aged 50
years or older reflects Swiss hospitalization data and,
thus, ensures consistency in our economic results. Pa-
tients that occupy a hospital bed for only a few hours
were taken into account here, which may explain, in
part, why this value is in accordance with a Swiss source
that indicated a hospitalization probability of 70% at
age 85 years, but not with two international sources that
hinted at a probability of approximately 10% only from
age 40 onwards [9, 35, 47]. The latter value was used as a
lower boundary in sensitivity analysis.
This study focused on the occurrence and impact of
osteoporosis-attributable hip, vertebral, and distal
forearm fractures. An assessment of total osteoporosis-
related fracture occurrence, resource use and cost would
have to take into account additional fracture sites, such
as the humerus, ribs and pelvis, but it was not under-
taken for reasons of data availability. Another slight
tendency for the model to underestimate the impact of
osteoporosis may have been introduced by our not
considering osteoporotic fracture occurrence under the
age of 50 years. Due to a lack of data, inpatient reha-
bilitation episodes caused by vertebral and distal fore-
arm fractures could not be taken into account, which
may have impacted on costs estimates.
In summary, in Switzerland the incidences of oste-
oporotic hip, vertebral and distal forearm fractures will
rise, respectively, by 33%, 27%, and 19%, between
2000 and 2020, if current prevention and treatment
patterns are maintained. Corresponding absolute frac-
ture numbers per year will rise by 36%, 31%, and
23%. The increase in hip fractures will be most pro-
nounced. Main causes are (1) a shift toward higher
ages within the population from age 50 years on, (2) a
relative growth of the population from age 50 on
within the total population, and (3) absolute popula-
tion growth. Main assumptions are that demographic
reality will essentially confirm the SFSO main scenario
and that age- and gender specific incidence rates will
remain constant. Related direct medical inpatient costs
per year are predicted to increase by 33%
(CHF232.8 million), but this result is affected by
uncertainty due to a lack of knowledge of future
developments of treatment patterns, economic circum-
stances, and resource unit prices. Moreover, currently,
total direct medical costs cannot be estimated due to
missing data on outpatient costs. When additional
information becomes available, this modeling frame-
work can be used for a re-assessment.
In more general terms, this modeling framework,
which focuses on hip, vertebral, and distal forearm
fractures, can be applied to a wide variety of situations
in order to forecast future developments and assess the
impact of changing medical practice and changing
economic circumstances. The incorporation of addi-
tional fracture sites is also feasible. Limitations will
usually be due to the limited availability of adequate
input data.
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Abstract
Summary A simulation model adopting a health system
perspective showed population-based screening with DXA,
followed by alendronate treatment of persons with osteo-
porosis, or with anamnestic fracture and osteopenia, to be
cost-effective in Swiss postmenopausal women from age
70, but not in men.
Introduction We assessed the cost-effectiveness of a popula-
tion-based screen-and-treat strategy for osteoporosis (DXA
followed by alendronate treatment if osteoporotic, or osteo-
penic in the presence of fracture), compared to no interven-
tion, from the perspective of the Swiss health care system.
Methods A published Markov model assessed by first-order
Monte Carlo simulation was refined to reflect the diagnostic
process and treatment effects. Women and men entered the
model at age 50. Main screening ages were 65, 75, and
85 years. Age at bone densitometry was flexible for persons
fracturing before the main screening age. Realistic assump-
tions were made with respect to persistence with intended
5 years of alendronate treatment. The main outcome was cost
per quality-adjusted life year (QALY) gained.
Results In women, costs per QALY were Swiss francs
(CHF) 71,000, CHF 35,000, and CHF 28,000 for the main
screening ages of 65, 75, and 85 years. The threshold of
CHF 50,000 per QALY was reached between main
screening ages 65 and 75 years. Population-based screening
was not cost-effective in men.
Conclusion Population-based DXA screening, followed by
alendronate treatment in the presence of osteoporosis, or of
fracture and osteopenia, is a cost-effective option in Swiss
postmenopausal women after age 70.
Keywords Alendronate . Bone densitometry . Cost-utility
analysis .Modelling studies . Osteoporosis . Switzerland
Introduction
Osteoporosis is a chronic, systemic disease, characterised
by low bone mass and deterioration of bone micro-
architecture, leading to increased fracture risk [1]. Osteo-
porotic fragility fractures may occur at any skeletal site [2].
However, fractures of the hip, the spine and the distal
forearm are the most frequent osteoporotic fracture types
[3], representing 82% and 75% of all incident osteoporotic
fractures in Swiss women and men, respectively [4]. The
lifetime risk of any osteoporotic fracture approximates 50%
in women and 20% in men [5]. Fractures result in
significant morbidity [6, 7], mortality [8, 9], and reductions
in quality of life [10].
Osteoporosis has a profound and growing impact on
health care resource utilization, especially in industrialized
countries. The direct expenditures for the treatment of
osteoporotic fractures were estimated at US dollar (USD)
10–15 billion per year for the USA [11], a figure which is
consistent with Swiss francs (CHF) 713 million reported for
Switzerland for the year 2000 [4]. These costs are expected
to substantially increase in the coming decade, due to the
overall ageing of the population and to the exponential
increase of fracture incidence with age [4, 12].
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Drug therapy of osteoporosis is generally indicated in
patients who have had a prior fragility fracture and in
patients who have osteoporosis according to the WHO
densitometric definition (i.e., T-score≤−2.5 SD) [1].
Alendronate, an aminobisphosphonate, has been previously
shown, in randomised controlled primary endpoint fracture
trials [13–15] and in meta-analyses of such trials [16, 17],
to reduce fracture risk at all clinically relevant sites,
including the hip, in postmenopausal women with osteo-
porosis defined as low BMD with or without prevalent
vertebral fractures. In addition, the efficacy and safety of
long-term treatment of osteoporosis with alendronate was
established for up to 10 years of continuous therapy [18].
Furthermore, the efficacy profile of alendronate for reduc-
ing fracture risk was established in men with primary
osteoporosis [19, 20] and in the most frequent form of
secondary osteoporosis, glucocorticosteroid-induced osteo-
porosis, in women and in men [21].
Several studies have suggested that the treatment of
osteoporosis with alendronate is cost-effective [22–30] with
an incremental cost-utility ratio (ICUR) of less than USD
50,000 per quality adjusted life year (QALY) gained.
However, these studies generally did not consider the cost
involved with the identification of cases of osteoporosis
which deserve therapeutic intervention, with only two
exceptions, one study in glucocorticosteroid-induced oste-
oporosis [30] and one recent publication by Schousboe et
al. [27]. In the latter work, the health benefits and costs of
universal screening of elderly women, followed by alendro-
nate treatment of those identified with osteoporosis
(screen-and-treat strategy) were assessed from the societal
perspective. The cost per QALY gained was estimated at
USD 43,000 and USD 5,600 for 65 and 75-year-old
women, respectively, while the intervention was found to
be cost-saving for older women [27]. However, this model
observed the screened populations from the age of mass
screening onwards only and did not take into account the
effect of cases identified and treated earlier (e.g., due to
fractures occurring before the main screening age).
In Switzerland, as in many other European countries,
bone densitometry with DXA is not accepted for mass
screening of osteoporosis and reimbursement is limited to
indications resulting from case-finding strategies. Drug
treatment is reimbursed for persons with a T-score≤
−2.5 SD or in the presence of one or more fragility
fractures. Whether and for which subset of the population
mass screening with DXA, followed by drug treatment
where indicated, would be cost-effective remains unknown.
Using an adapted version of our published model [12],
the present study aimed at assessing the cost-effectiveness
of mass bone densitometry screening plus subsequent
alendronate therapy, compared to no drug treatment of
osteopenia and osteoporosis, in the Swiss population from
age 50 onwards, from the perspective of the Swiss health
care system. We took into account the impact of earlier
fracture events, which have already led to “pre-screening
age” diagnostic activities. We hypothesized that even if the
diagnostic process is taken into account in the modelling,
the cost-effectiveness of subsequent drug intervention will
still be preserved in specific patient groups.
Materials and methods
The cost-effectiveness of two alternative strategies was
evaluated in a simulation-based incremental cost-utility
analysis from the perspective of the Swiss health care
system. For this purpose, a non-intervention strategy was
compared to a screen-and-treat strategy defined as i) bone
densitometry screening with DXA at a predefined main
screening age or if a fracture occurred after age 50, and ii)
alendronate (FOSAMAX®; Merck & Co) treatment in
subjects with osteoporosis (T-score≤−2.5 SD), or with
confirmed osteopenia (T-score > −2.5 SD but < −1.0 SD)
after a fracture event [31]. The time horizon for analysis
was life-long from age 50 on in the main analysis. Direct
medical costs were taken into account regardless of payer.
For women and men, the outcomes of the screen-and-
treat strategy were assessed for main screening ages of 65,
75, and 85 years, and for three treatment options each:
treatment with alendronate for 5 years [25] with full
persistence (to assess the theoretical potential); treatment
with alendronate for 5 years with realistic persistence; and
treatment with alendronate for 10 years with realistic
persistence.
Additional specifications were: re-screening once after
3 years if osteopenic at first measurement (in the absence of
fracture); assessment of all persons presenting with a
fracture and treatment if osteopenic or osteoporotic;
treatment initiation without additional screening if a
fracture occurred and an earlier screening had already
confirmed the presence of osteopenia; no repeated initiation
of alendronate treatment in the same person; no initiation of
treatment after age 95.
The main outcome was the incremental cost per QALY
gained (incremental cost-utility ratio; ICUR) of each
screen-and-treat scenario vs. the no intervention scenario.
In the absence of an accepted cost-effectiveness thresh-
old for Switzerland, ICUR results of less than CHF 50,000
per QALY gained were regarded as cost-effective. Taking
different price structures into account [32], one can regard
this choice as roughly equivalent to the thresholds of USD
50,000 per QALY, and of British pound (GBP) 20,000–
30,000 per QALY, which have been used for the USA and
the United Kingdom, respectively [33, 34]. CHF 1 equalled
USD 0.80 on June 30, 2006.
1482 Osteoporos Int (2007) 18:1481–1491
Model characteristics
Key model characteristics were previously described [12].
Briefly, a Markov state transition model with four mutually
exclusive health states (alive without fracture; alive with at
least one distal forearm or vertebral fracture, but no hip
fracture; alive with at least one hip fracture; dead) was
developed to simulate the number of osteoporotic hip,
vertebral, and distal forearm fractures as a function of
demographic change and other influences. This model was
analysed using individual, first-order Monte Carlo simula-
tion, and was pre-designed to be adaptable for assessing the
impact of different screening, prophylactic, and treatment
strategies on fracture occurrence and associated cost,
allowing for a wide variety of scenarios regarding planned
medication usage, drug efficacy, and individual persistence
with treatment. Cycle length was one month. For the
purpose of this study, the model was adapted as follows:
1. The increase in relative fracture risk observed in
persons with a history of previous fracture; in those
suffering from osteopenia or osteoporosis; and in
nursing home residents was additionally modelled.
The technical implementation was such that the average
gender- and age-specific fracture incidences remained
unaffected.
2. The probability of having osteopenia or osteoporosis at
model entry, or of developing any of these conditions,
was modelled using gender- and age-specific preva-
lence estimates and transition probabilities derived
from these.
3. The impact of alendronate usage was modelled using
published relative risks (RRs).
4. Age at model entry was kept constant while screening
age was considered variable in the different scenarios,
in order to accommodate for the fact that at a given
main screening age, some persons may already have
been identified with and treated for osteoporosis.
5. In order to take into account the difference between
fracture-associated mortality and mortality causally
related to fracture, the estimates of life years gained
through alendronate usage were corrected downwards
in a separate step, outside the main model. The “life
expectancy component” of the QALY results was
corrected in the same way.
Model inputs
Published or publicly available Swiss data sources were used
whenever available. Otherwise, European data were preferred
to US data, and were adjusted for regional differences within
Europe. Gender- and age-specific population-level fracture
risks and other models inputs used in the previously published
model version were retained with the exception of osteopo-
rosis attribution probabilities, which were no longer used to
model osteoporotic causation of fracture events [12]. Addi-
tional inputs comprised the following.
Prevalence of osteopenia/osteoporosis was assumed to
be similar as seen in the NHANES III study for a caucasian
US population, based on femoral neck BMD measurements
[35, 36]. In the absence of published Swiss BMD data, a
local DXA reference database from the Bern Canton
supported this assumption. Technical implementation used
the results of the Rotterdam Study, with data points
available for both genders and all relevant age groups
[37]. Compared with NHANES III, the Rotterdam data
showed a higher prevalence, consistent with the north-south
gradient of osteoporosis prevalence in Europe. Therefore, a
downwards adjustment was performed, using the following
correction factors: 0.80 for osteopenia and osteoporosis in
women; 0.65 for osteoporosis and 0.75 for osteopenia in
men. This resulted in average prevalences of 23% and 8%
(osteoporosis), and of 49% and 46% (osteopenia), in women
andmen from age 50, respectively. These figures are consistent
with the NHANES III results [35, 36]. The incidence of
osteopenia and osteoporosis was estimated using transition
probabilities derived from these prevalence data.
Prevalence of any previous fracture was derived from a
recent meta-analysis exploring the relationship of any
previous fracture with age, sex and bone mineral density
in 15,259 men and 44,902 women from 11 cohorts
followed for a total of 250,000 person-years [38].
Relative fracture risks In the presence of osteoporosis or
osteopenia, RRs of 2.7 or 1.3, respectively, as reported in
the Rotterdam Study, were used for non-vertebral fractures
in women and men [37]. Identical RRs were assumed for
vertebral fractures [39]. BMD-adjusted RRs of 1.7 for
women and of 2.0 for men were used to take into account
the presence of previous fracture [38]. For nursing home
residents, a RR for hip fracture of 3.5 was assumed, based
on the only recent Swiss publication available [40]. This
figure is consistent with previously published Swiss [41]
and US data [42, 43]. No increased risk of vertebral and
distal forearm fracture was assumed for this group [44, 45].
The above RRs compare persons who have the risk factor
of interest with persons who do not have it. In combination
with absolute fracture risk (gender- and age-specific, but
averaged across other risk factors), and gender- and age-
specific patterns of risk factor prevalence, they provided a
basis for deriving individualised fracture risks as they were
finally used in the modelling.
The RR of fracture during alendronate treatment in
women with osteoporosis was generally assumed to be 0.5,
in accordance with published primary endpoint trials and
Osteoporos Int (2007) 18:1481–1491 1483
meta-analyses [13–17, 28]. However, a more conservative
RR of 0.6 was assumed for non-vertebral fractures after age
85 [29, 46]. In women with osteopenia, the RR was
conservatively assumed to be 0.7 for vertebral fractures
[15] and 1.0 for other fractures. Identical assumptions were
used for men [20]. The effect of alendronate has been shown
to be present early in treatment [47]. For the purpose of this
analysis, it was assumed to be present from day 1 of therapy,
given that the above RR estimates represent averages across
the entire observation periods of the underlying studies. After
the end of alendronate administration, we assumed a linear
decline of the alendronate effect to zero over a 5-year period
[18, 48], or over a period equal to the given person’s
treatment duration, whichever was shorter.
Persistence with alendronate treatment was assumed to
decline linearly from 100% to 65% during year 1 and from
65% to 45% between end of year 1 and the end of the
intended duration of use [49]. It was assumed that those
who stopped drug treatment prematurely did no longer
accrue drug costs.
Mortality Twenty-five percent of the deaths associated with
hip fracture were considered to be causally related in the
base case scenario [50]. Consequently, the life years gained
through alendronate usage, as reported by the model, were
multiplied with a correction factor of 0.25. No such
adjustment was made for vertebral fracture-associated
excess deaths whose number was considered to be too
low to meaningfully impact on the overall results, espe-
cially when compared to the remaining uncertainty about
hip fracture-related excess mortality [48, 51]. To account
for an increased general morbidity of persons admitted to
nursing homes, in the absence of published data, a
correction factor of 0.9 was applied to the crude hip
fracture-related extra time spent in nursing homes, for the
base case analysis.
Utilities associated with health states As no Swiss data
were available, population-based European (Danish) data
were used as shown in Table 1 [23, 52]. These baseline
utilities were adjusted downwards after fracture occurrence,
by applying multiplication factors as reported by Kanis et
al. (Table 2) [53]. It was assumed that 2nd year factors
would also apply for subsequent years. In addition, 1st
year and subsequent years factors for the combination of a
hip and a clinical vertebral fracture were assumed to be
0.489 and 0.714 [27, 54]. Utility and multiplication factor
measurements involved the time trade off method and the
EQ-5D [52–54].
Costs Unit cost estimates were real cost estimates for the
year 2000. The monthly cost of alendronate treatment was
set at CHF 61.36, based on the public price of marketed
alendronate in Switzerland in 2005 adjusted for the health
system-specific price inflation between 2000 and 2005 of
3.4%, as published by the Swiss Federal Office of Statistics
(SFOS). Based on expert opinion and Swiss tariff lists, the
cost of each screening episode was estimated at CHF 300,
covering bone densitometry and a medical consultation
with typical services performed. Daily inpatient costs were
CHF 1,009 for acute care hospitals, CHF 440 for inpatient
rehabilitation facilities, and CHF 187 for nursing homes, as
reported by the SFOS for the year 2000. Overall inpatient
costs were modelled individually as previously described
[12]. To give some reference points, average acute care
length of stay was 17.4 days for hip fracture, 18.0 days for
vertebral fracture and 6.4 days for distal forearm fracture.
The probability of being hospitalised was assumed to be
33% after a vertebral fracture coming to clinical attention
[3, 55] and 53% after a distal forearm fracture [12].
Participation in an inpatient rehabilitation program after
hip fracture was assumed to occur in 68% of women and
36% of men, with a length of stay of 59 and 54 days,
respectively [56]. Ambulatory treatment costs post fracture
was estimated at CHF 6,442 for a hip fracture, based on
published data [57]. They were estimated at CHF 2,250 for
a vertebral fracture and at CHF 1,750 for a distal forearm
fracture, irrespective of whether an initial hospitalisation
Table 1 European (Danish) population utility values1
Age Average utility
50 0.917
55 0.9199
60 0.8992
65 0.8882
70 0.8939
75 0.863
80 0.8529
85 0.8339
1 Pedersen et al. 2003 [23, 52].
Table 2 Utility correction factors
Fracture site Female,
1st year
Male,
1st
year
Female,
subsequent
years
Male,
subsequent
years
Wrist1 0.977 0.977 0.999 0.999
Vertebrae1 0.820 0.777 0.913 0.912
Hip1 0.792 0.792 0.813 0.813
Hip and clinical
vertebral
fracture2
0.489 0.489 0.714 0.714
1Kanis et al. 2004 [53].
2Estimated based on Tosteson et al. 2001 [54] and Schousboe et al.
2005 [27].
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occurred. These estimates were based on expert opinion as
there were no published Swiss data available.
Discount rate The discount rate for costs and QALYs was
set at 3%.
Sensitivity analysis
In the base case scenarios, model entry was at age 50 for all
persons, which allowed to take into account the impact of
cases of osteoporosis or osteopenia with intercurrent
fracture, identified before the main screening age. In
alternative scenarios, intended for comparison purposes,
the simulated persons entered the model at the main
screening age, i.e., their previous diagnosis and treatment
history was neglected.
Additional, univariate sensitivity analyses were con-
ducted to identify influential input parameters. Specifically,
average population fracture risks; the risk reduction
achieved with alendronate; the utility reduction due to
fracture events; and most cost parameters were varied
by ±30%. The cost of outpatient fracture treatment was
varied by ±50%, due to the higher level of uncertainty
present in the underlying estimates. The linear offset post
alendronate administration was set to 0.4 or 1.6 times the
treatment duration, corresponding to a 2-year or 8-year
linear offset for a treatment duration of 5 years. Persistence
with alendronate treatment was assumed to decline from
100% to either 40% or 80% during year 1, and to decline
further to either 20% or 60% between end of year 1 and the
end of the intended duration of use [49]. The correction for
non-causally related hip fracture-associated deaths was set
to 15% or 50%, and the correction of hip fracture-related
nursing home time for increased general co-morbidity of
nursing home residents was set to 0.6 or 1.0, the latter
representing no correction. The probability of a new
nursing home admission after hip fracture was set to 10%
or 25% [12]. The discount rate was set to 0% or 6%.
Subsequently, probabilistic sensitivity analyses were run
on the main scenarios. Triangular distributions, based on
the base case values and the above described ranges of
variation, were used to vary the above-listed parameters
jointly. As an exception, a uniform distribution was used to
vary the correction of hip fracture-related nursing home
time for increased general co-morbidity of nursing home
residents, in the absence of published values. The discount
rate was not varied in probabilistic sensitivity analysis.
Technical implementation
The model was implemented using TreeAge Pro 2006
Suite® (TreeAge, Williamstown, USA). TreeAge’s option
to independently seed each model iteration allowed to
greatly reduce the amount of random variation present in
the simulation results. Additional statistical analyses were
performed in Stata/SE®, version 9 (Stata Corporation,
College Station, USA). Main scenarios and univariate
sensitivity analyses were based on 100,000 simulated
persons per arm, for each scenario. Probabilistic sensitivity
analyses used 500 different sets of input parameters
(randomly drawn from the above-mentioned triangular
distributions) and 2,000 simulated persons per set of input
parameters and arm [27].
Model validation
All validations performed on the previously published
model [12] retained their validity. Expected gender- and
age-specific prevalences of osteoporosis and osteopenia
were reproduced correctly. After model calibration, the
overall fracture incidence rates found for a cohort followed
for the rest of their lives from age 50 onwards, without
alendronate treatment, deviated only slightly from the
incidence rates calculated from the previously published
model (deviations in women: hip fracture 0.7%; vertebral
fracture 0.2%; distal forearm fracture 0.2%, deviations in
men: hip fracture −0.3%; vertebral fracture 0.0%; distal
forearm fracture −3.3%). A simulation of 50,000 virtual
persons receiving alendronate, under the assumption of
perfect persistence and a relative risk of fracture of 0.5,
correctly reduced fracture incidences by 50%. Two
scenarios mimicking the previously published models
of Christensen et al. [23] and Johnell et al. [25] delivered
similar results in terms of expected relative fracture risk
reduction. Calculation of 95% confidence intervals based
on bias-corrected bootstrapping using 1,000 repetitions
confirmed standard errors for the main outcomes of interest
to be sufficiently small compared to effect sizes. (Data not
shown).
Results
Results for the primary outcome measure, incremental cost
per QALY gained (ICUR), are shown in Table 3, for both
genders. Table 3 covers the base case scenarios (where all
persons entered the model at age 50) as well as the
alternative scenarios (where all persons entered the model
at the main screening age; to enhance comparability with
results published earlier by Schousboe et al. [27]). The
incremental costs of, and QALYs gained with a screen-and-
treat strategy compared to no intervention, assuming model
entry at age 50 and 5 years of intended treatment with
alendronate if applicable, under realistic persistence
assumptions, are shown for women and men in Table 4.
Osteoporos Int (2007) 18:1481–1491 1485
ICUR results were better when model entry was at the
main screening age (i.e., when the possibility of earlier
diagnosis and treatment was disregarded); better in women
than in men; better if perfect persistence was assumed; and
better if the intended treatment duration was extended from
5 to 10 years under realistic persistence assumptions.
However, the latter was not observed when the main
screening age was set to 85 years.
In women, the ICUR of the screen-and-treat strategy
compared to no intervention was less than CHF 50,000 for a
main screening age of 75 years or higher, in the base case
scenario. In the alternative scenarios, ICUR results were
below or around CHF 50,000 for all main screening ages
considered. Although the alternative scenarios showed overall
improved cost-effectiveness results, the relative rank order of
the assessed strategies remained identical. An additional
analysis under realistic persistence assumptions showed that,
in women, a screen-and-treat strategy using a main screening
age of 70 years lead to ICURs of CHF 49,101 and CHF
42,141 for 5 and 10 years of intended alendronate treatment,
respectively. However, the screen-and-treat approach did not
appear to be cost-effective for a main screening age of 65 years
or below, or in men.
The impact of univariate sensitivity analysis on the
ICUR is shown in Table 5, for a representative scenario
(women; model entry at age 50; main screening age
75 years; intended duration of alendronate treatment 5 years;
realistic persistence). For this scenario, parameter changes
favouring the comparator strategy yielded moderate
increases of the ICUR, which remained below or very
close to CHF 50,000 in all instances. Variation of the risk
reduction achieved with alendronate, of the duration of the
residual alendronate effect after the end of drug adminis-
tration, and of the cost of drug treatment had the strongest
impact. The parameters which exerted the smallest influ-
ence were the correction for increased general morbidity of
persons admitted to nursing homes, the probability of a new
nursing home admission after hip fracture, and the cost of
outpatient fracture treatment.
For this same scenario, probabilistic sensitivity analysis
indicated that the cost-effectiveness criterion of CHF
50,000 per QALY gained was met in 79% of cases, with
a 95% confidence interval for the ICUR reaching from cost-
saving to CHF 79,525 per QALY gained (Fig. 1). Under
identical assumptions, but with the main screening age set
to 65 years, the CHF 50,000 per QALY threshold was only
reached in 16% of the cases.
Discussion
The present study demonstrates that, from the perspective
of the Swiss health care system, mass bone densitometry
screening at or after age 70, plus subsequent alendronate
therapy for 5 or 10 years (screen-and-treat strategy for
osteoporosis and osteopenia), is a cost-effective interven-
tion in women, with an ICUR around or below CHF 50,000
per QALY gained. This finding is based on realistic
assumptions with respect to persistence with drug treatment
and takes into account the impact of diagnostic and
treatment activities before the age of mass screening,
induced by “pre-screening age” fracture occurrence. It is
Table 4 Incremental cost of and quality-adjusted life years (QALYs)
gained with a screen-and-treat strategy compared to no intervention,
per 1,000 persons
Women Men
Main screening age 65 years
QALYs gained (years) 8.34 2.05
Incremental cost (CHF) 591,920 405,190
Main screening age 75 years
QALYs gained (years) 9.85 2.04
Incremental cost (CHF) 348,750 251,570
Main screening age 85 years
QALYs gained (years) 5.44 1.01
Incremental cost (CHF) 153,340 120,210
Specifications: model entry at age 50; intended duration of alendro-
nate treatment 5 years; realistic persistence
Table 3 Incremental cost-utility ratio in CHF per quality-adjusted life
year gained, for women and men, by main screening age
Main
screening
age
5 years
alendronate,
persistence
100%
5 years
alendronate,
realistic
persistence
10 years
alendronate,
realistic
persistence
Women
Age at model entry, 50 years
65 years 55,729 70,995 61,280
75 years 24,170 35,4121 30,155
85 years 19,433 28,170 34,341
Age at model entry equals main screening age
65 years 45,545 55,533 46,805
75 years 5,045 11,904 7,245
85 years Cost-saving Cost-saving Cost-saving
Men
Age at model entry, 50 years
65 years 149,682 197,460 162,509
75 years 95,559 123,094 113,178
85 years 93,184 118,945 123,973
Age at model entry equals main screening age
65 years 135,638 176,670 147,991
75 years 60,269 85,911 73,526
85 years 30,763 48,268 50,413
1CHF 21,502 per quality-adjusted life year gained if assuming no
diagnostic or treatment activity before the age of mass screening.
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hence in line with the stated hypothesis. In contrast, a
screen-and-treat strategy for osteoporosis and osteopenia
does not appear to be cost-effective in men.
Increasing the intended duration of alendronate treatment
from 5 to 10 years leads to improved ICUR results in most
cases. However, for a main screening age of 85 years, this
was no longer true. At this age, all-cause mortality rates are
very high and cost savings due to avoided fracture events
may no longer be able to outweigh the additional cost of
further treatment.
Our results demonstrate further that in situations where
fixed upfront costs (not influenced by persistence; such as
screening costs) have a substantial role, sub-optimal persis-
tence can have a relevant negative impact on ICUR results.
Our screen-and-treat strategy assumed, in contrast to
current clinical practice in Switzerland and other countries
[58], that all persons fracturing before the main screening
age would immediately be assessed, and treated with
alendronate if osteopenic or osteoporotic. Not allowing for
such “pre-screening age” diagnostic and treatment activities
leads to improved cost-effectiveness results because on
average, alendronate is now administered at a higher age
and when fracture incidences are also higher, at the cost of not
protecting an easily identifiable risk group at an earlier age.
To our knowledge, the only other modelling study
assessing a mass screen-and-treat strategy for osteoporosis
was recently published by Schousboe et al. [27]. These
authors compared the combination of DXA screening plus
alendronate treatment from a US perspective. Their ap-
proach was conceptionally close to ours, with some
remarkable differences. The present model used Swiss or
European data whenever available; all scenarios were
assessed for women and for men; the strategies modelled
took into account osteopenia in addition to osteoporosis;
and realistic assumptions were made with respect to
persistence with alendronate treatment in the base case
analysis. Most importantly, we observed the target popula-
tion from age 50 onwards (and not from the age of mass
screening onwards, which scotomizes any diagnostics
performed earlier, and treatments administered earlier, due
to fracture occurrence before the main screening age). This
scotomization and a related difficulty to individually model
“pre-screening age” fracture-induced changes in health-
related quality of life and utility may have lead to an
overestimation of the cost-effectiveness of the screen-and-
treat approach, in particular when a very high main
screening age was chosen. In order to clarify this point,
we performed alternative assessments with model entry at
Table 5 Univariate sensitivity analysis of incremental cost-utility ratio for women
Parameter varied Range of variation Favours
screening/
alendronate use
Baseline Favours
comparator
strategy
Fracture risk (average population
risk)
+30%/−30% 22,775 35,412 45,512
Fracture risk, effect of alendronate Relative reduction of risk, +30%/−30% 18,062 35,412 52,543
Duration of effect of alendronate after
end of administration
Linear offset, 1.6/0.4 times duration of administration 25,409 35,412 50,131
Persistence (persons taking drug) Decline to 40%/80% in year 1, further decline to 20%/
60% between end of year 1 and end of intended
duration of use
30,149 35,412 46,374
Causally related hip fracture-
associated deaths
50%/15% 25,525 35,412 41,904
Correction for increased general
morbidity in persons admitted to
nursing homes
1.0/0.6 34,751 35,412 37,395
Probability of new nursing home
admission after hip fracture
10%/25% 31,334 35,412 37,989
Disutility factors Relative utility reduction, +30%/−30% 29,272 35,412 44,812
Cost of alendronate −30%/+30% 22,002 35,412 48,822
Cost of diagnostic work-up before
initiation of alendronate therapy
−30%/+30% 29,988 35,412 40,836
Cost of inpatient treatment inclusive
of nursing home stays
+30%/−30% 28,325 35,412 42,499
Cost of outpatient fracture treatment −50%/+50% 34,289 35,412 36,535
Discount rate 0%/6% 20,904 35,412 47,807
Specifications: model entry at age 50, main screening age 75 years; intended duration of alendronate treatment 5 years; realistic persistence
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the main screening age. The resulting set of more favourable
ICUR values was entirely consistent with the results reported
by Schousboe et al. [27]. In both cases, the gain in cost-
effectiveness achieved by choosing a higher main screening
age was distinctly bigger than in our analyses observing the
target population from age 50 onwards. Observing the
target population from the age of mass screening onwards
only, or otherwise disregarding diagnostic and treatment
activities before the main screening age, tends to overesti-
mate cost-effectiveness in general, and the advantages of
choosing a high screening age in particular.
This study has some limitations. The proposed results
and conclusions are model-based, which always implies a
simplification of reality. This remains true although we
adapted our published model [12] to incorporate the
screening and diagnostic process (in contrast to other
modelling studies addressing the cost-effectiveness of
alendronate [23, 25]); to take into account increases in
relative fracture risk in persons with anamnestic fractures or
with low BMD; and to correct for the discrepancy between
fracture-associated deaths and deaths causally related
to fracture [23, 25]. The co-morbidity patterns of osteopo-
rotic fracture patients are likely to differ from those of the
general population and we implemented a correction for
increased general morbidity in persons who were admitted
to a nursing home post hip fracture. However, little detailed
knowledge is available on this topic, which may have a
significant impact on patient outcomes and on the cost-
effectiveness of intervention which could not be adequately
reflected in our model and deserves further research.
The model did not encompass all types of osteoporotic
fractures but was limited to three typical fracture sites.
About 18–25% of osteoporotic fractures were shown to
occur at other skeletal sites not considered in the present
analysis [4]. This may have led to a certain underestimation
of the cost-effectiveness of the screen-and-treat approach.
We made realistic assumptions with respect to
persistence with drug treatment, but in order to limit
complexity, it was assumed that no further drug costs
were accrued by those persons who stopped taking the
drug prematurely. Moreover, given that alendronate is
currently taken as a weekly tablet, the possibility of
additional compliance effects (such as reduced effec-
tiveness due to omission of individual doses or taking
the drug in the wrong way) was neglected. This may
have caused a certain overestimation of the cost-
effectiveness of the screen-and-treat approach.
Only some of our model inputs could be based on published
or official Swiss data [12]. Other model inputs had to be
derived from various European or US sources, had to be
based on expert opinion, or were subject to relevant
uncertainty otherwise (e.g., persistence with drug treatment;
residual treatment effect after the end of drug administration).
However, univariate and probabilistic sensitivity analyses
confirmed the robustness of the ICUR results. Based on
variation within a ±30% range, the risk reduction achieved
with drug treatment was the most sensitive single parameter.
The applicability of our results is in essence limited to
Switzerland, as Swiss cost and resource use data were used.
Some transferability to other industrialised countries with
similar cost and age structures can be assumed, but cannot
be taken for granted. Transferability to other treatments of
osteoporosis may neither be without problems. Separate
calculations would be required, based on a thorough
assessment of reported effect sizes, related levels of
empirical evidence, and other related input parameters (e.g.,
expected persistence).
Finally, this study did not assess the cost-effectiveness of
scenarios involving a pre-selection of sub-populations at
high risk of osteoporosis. Earlier studies have shown that
selective case-finding based on a combination of risk
factors, with or without radiographic absorptiometry,
Fig. 1 Probabilistic sensitivity analysis of incremental cost-utility
ratio of DXA-based screening and subsequent alendronate treatment,
compared to no intervention, for women. Specifications: model entry
at age 50; intended duration of alendronate treatment 5 years; realistic
persistence; main screening ages 65 years (top) and 75 years (bottom).
Slant lines represent the cost-effectiveness threshold of CHF 50,000
per quality-adjusted life year gained
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provided a better sensitivity and specificity in identifying
women with underlying osteoporosis than the currently
accepted criteria for reimbursement of DXA measurements
in Switzerland [59]. In addition, the pre-selection of women
and men at highest risk of osteoporosis, and who should
therefore undergo BMD measurement by DXA, based on
the determination of their 10-year absolute fracture risk
may considerably improve the cost-effectiveness of the
population-based screen-and-treat approach [60–64]. More
research work is required in this field.
In Switzerland, as in other European countries, universal
screening for osteoporosis with bone densitometry using
DXA is not recommended and patient identification solely
relies on case-finding strategies based on anamnestic
fractures and/or other risk factors for osteoporosis. For the
USA, medical interventions have been considered as cost-
effective from a societal point of view if their cost was
below USD 50,000–100,000 per QALY gained [33].
Allowing for different price structures in the USA vs.
Switzerland, the cost-effectiveness threshold adopted here,
of CHF 50,000 per QALY, is at the lower end of this range,
and was used in an assessment only taking into account
direct medical costs. It corresponds to 0.9 times the Swiss
gross domestic product (GDP) per capita in the year 2000
(while use of a factor of 1.4–2.1 times the GDP per capita
has been tentatively estimated for the UK [65]), and must,
thus, be considered as conservative. With this restrictive
assumption, this is the first European study to demonstrate
that population-based screening with bone densitometry by
DXA and subsequent alendronate treatment in the presence
of osteoporosis, or of anamnestic fracture and osteopenia, is
cost-effective in women from age 70 onwards and should,
therefore, be regarded as a valid option from a Swiss health
care system point of view.
Generic alendronates may become available in Switzer-
land in the future. By Swiss law, no cost-effectiveness
assessment of new generics is required if they are marketed
at least 30% below the price of the original drug [66].
Based on their lower price, such generic alendronates may
contribute to further improve the cost-effectiveness of the
screen-and-treat option. Our corresponding univariate sen-
sitivity analysis result of CHF 22,002 per QALY gained
reflects this theoretical potential, if it is assumed that the
clinical efficacy, tolerability and safety of the original
compound will be matched.
Although the incremental cost-utility ratio remains
superior if a high main screening age is chosen, the
difference seen is distinctly smaller than reported earlier
[27], leaving more room for the notion that it may be more
important from an individual, but also from a societal
perspective to avoid fracture events at a younger rather than
at a later age, despite higher absolute budget implications
due to differences in the size of the populations to be
screened. If and for which population segments the cost-
effectiveness of the screen-and-treat approach can be
further improved, e.g., by pre-selection of eligible candi-
dates for screening based on clinical risk factor profiles,
should be subject to further research.
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